GLP-1 drugs before anesthesia
Should GLP-1 receptor agonists be continued or withheld before anesthesia? Compare residual gastric-content studies with actual aspiration outcomes, and distinguish elective surgery from endoscopy.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 87 of 87
Recent evidence · past year
-
Preoperative GLP-1 Receptor Agonist Use and Postoperative Outcomes Across Plastic and Reconstructive Surgery: A Systematic Review and Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of 13 comparative studies including 17,426 adults undergoing plastic and reconstructive surgery, 8,745 of whom used GLP-1 RAs.
- Compared preoperative GLP-1 receptor agonist use with no use, pooling risk ratios with random-effects models.
- No association was found with wound dehiscence, surgical site infection, seroma, haematoma or venous thromboembolism, but hypertrophic scarring was higher (RR 1.55; 95% CI 1.01-2.38).
- The authors judge the evidence very low certainty and hypothesis-generating, favouring individualised perioperative management over routine restriction of GLP-1 RAs.
Original abstract (PubMed)
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for pre-operative weight loss before body-contouring procedures, yet their effects on wound healing are poorly characterised and evidence on post-operative complications is conflicting. METHODS: We searched PubMed, Embase, Cochrane, ClinicalTrials.gov and the WHO ICTRP (to May 2026) for comparative studies of pre-operative GLP-1 RA use versus no use in adults undergoing plastic and reconstructive surgery. Risk ratios (RR) were pooled using random-effects models (REML; Hartung-Knapp-Sidik-Jonkman confidence intervals [CI]); pre-specified population subgroups were compared. Analyses used R (version 4.3). RESULTS: In total, 13 studies (n = 17,426; 8,745 GLP-1 RA users) were included. Pre-operative GLP-1 RA use was not associated with wound dehiscence (RR 1.05; 95% CI 0.73-1.52), surgical site infection (RR 0.83; 0.60-1.16), seroma (RR 1.12; 0.67-1.87), haematoma (RR 1.13; 0.67-1.90) or venous thromboembolism (RR 0.61; 0.34-1.08). Hypertrophic scarring was increased (RR 1.55; 95% CI 1.01-2.38). Tests for differences between the general-population, post-bariatric and reconstructive subgroups were non-significant for all outcomes except surgical site infection (P < .001), which showed lower rates in the reconstructive subgroup. CONCLUSION: In adults undergoing plastic and reconstructive surgery, pre-operative GLP-1 RA use was not associated with an overall increase in post-operative complications, apart from a modest increase in hypertrophic scarring, and population subgroups did not differ except for surgical site infection. Given the very low certainty of evidence, these findings are hypothesis-generating and support individualised perioperative management rather than routine restriction of GLP-1 RAs. LEVEL OF EVIDENCE: Level III (risk/prognostic study).
-
What's Coming Up Next? The Physiology of Gastroparesis and GLP-1 Agonists.
AI summary of the abstract, unverified
- This is a narrative review of GLP-1 physiology and the upper gastrointestinal effects of GLP-1 receptor agonists, with no original patient data reported in the abstract.
- It covers approved peptide, nonpeptide, and combined GLP-1/GIP agonists, and the nausea, vomiting, and delayed gastric emptying they can cause.
- The authors describe a theoretical risk of pulmonary aspiration from retained gastric contents in patients undergoing anesthesia for endoscopy or surgery.
- Management options named include diet changes, antiemetics, and prokinetic treatments, and newer agents acting through GIP, glucagon, or other pathways are still in testing.
Original abstract (PubMed)
Glucagon-like peptide-1 (GLP-1) is an incretin to regulate glycemia, activates peripheral and central neural pathways to control appetite, and inhibits upper gut transit to reduce food intake. Peptide and nonpeptide GLP-1 receptor agonists (GLP-1RAs), as well as a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), agonist are approved for type 2 diabetes, weight reduction, and other indications. GLP-1RA therapy can be complicated by upper gastrointestinal (GI) symptoms, including nausea and vomiting. Delayed gastric emptying secondary to GLP-1RAs may be influenced by drug pharmacokinetics, associated neuropathy, and development of tachyphylaxis with repeated dosing. A theoretical risk of pulmonary aspiration from retained gastric contents is concerning for patients undergoing anesthesia before endoscopy or surgery. Managing upper GI complications of GLP-1RA therapy includes diet modifications, antiemetic medications, and treatments that stimulate gastric emptying. Newer agents in testing include nonpeptide GLP-1RAs and GLP-1RAs acting in concert with GIP, glucagon, or other receptor-mediated pathways.
-
A practical framework for using GLP-1 RAs, SGLT2i, and MRAs with contemporary immunosuppression in kidney transplant recipients.
AI summary of the abstract, unverified
- This is a narrative review presenting a practical framework for adding GLP-1 RAs, SGLT2 inhibitors, and MRAs to kidney transplant immunosuppression.
- The authors describe evidence in transplant recipients as limited, suggesting possible benefits for glycemia, weight, blood pressure, proteinuria, and cardiorenal risk without routine immunosuppression changes.
- Whether these agents improve patient or graft survival is unproven, and GLP-1 RA gastrointestinal effects may alter oral immunosuppressant absorption, warranting trough monitoring.
- The authors advise individualized, sequential introduction with monitoring of graft function, electrolytes, volume status, and immunosuppressant exposure, plus drug-specific sick-day and perioperative holds.
Original abstract (PubMed)
PURPOSE OF REVIEW: Calcineurin inhibitors (CNIs) remain central to kidney-transplant (KTX) immunosuppression (IS) but contribute to nephrotoxicity and cardiometabolic (CM) complications which negatively affect patient and graft survival. This review presents a practical framework for adding glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitors (SGLT2i), and mineralocorticoid receptor antagonists (MRAs) to established IS regimens. These agents complement individualized optimization of IS, including CNI-sparing strategies when indicated. RECENT FINDINGS: Evidence in KTX recipients remains limited, but available studies suggest that these agents may improve glycemic control, weight, blood pressure, proteinuria, and cardiorenal risk without routinely requiring changes to IS choice or dose. Whether these changes improve patient and graft survival remains unproven. GLP-1 RA related gastrointestinal effects may alter oral IS absorption, warranting continued CNI trough monitoring, particularly when significant gastrointestinal symptoms occur after initiation or dose escalation. SGLT2i require assessment of volume status, renal-function, and infection risk. MRAs may compound CNIs associated hyperkalemia and early eGFR decline, requiring close potassium and renal-function monitoring. SUMMARY: These therapies may extend cardiorenal benefits observed in nontransplant chronic kidney disease to selected KTX recipients. Their use should be individualized, introduced sequentially, and supported by monitoring of graft function, electrolytes, volume status, blood pressure, and IS exposure. Temporary withholding should follow drug-specific perioperative and sick-day guidance, particularly for SGLT2i.
-
Surgical Management of Hidradenitis Suppurativa: Current Evidence and Practical Guidance.
AI summary of the abstract, unverified
- This review summarizes surgical management of hidradenitis suppurativa, a chronic inflammatory disease that can progress to tunnels, fibrosis, and scarring.
- It covers when to refer for surgery, how lesion architecture and anatomic site guide procedure choice, and how perioperative biologics can be combined with operative treatment.
- Deroofing is described as most suitable for localized tunnels, while wide excision offers more durable local control for diffuse or deeply interconnected disease.
- The authors emphasize individualized procedure selection, integration with medical therapy, and standardized outcome reporting, and also discuss ultrasound staging and GLP-1 receptor agonists as adjuncts.
Original abstract (PubMed)
Hidradenitis suppurativa is a chronic inflammatory skin disease that frequently progresses from recurrent nodules and abscesses to tunnels, fibrosis, scarring, and substantial quality-of-life impairment. Medical therapy is essential for controlling inflammatory activity, but surgery remains central to the management of structurally irreversible disease. This review summarizes the role of surgery within contemporary hidradenitis suppurativa care, with attention to when surgical referral should occur, how lesion architecture and anatomic site influence procedure selection, and how perioperative biologic therapy can be integrated with operative treatment. Tissue-sparing approaches such as deroofing are most appropriate for localized tunnels, whereas wide excision offers more durable local control for diffuse or deeply interconnected disease. Outcomes are shaped not only by procedure choice, but also by reconstruction strategy, postoperative wound care, anatomic constraints, and access to coordinated multidisciplinary care. The review also discusses evolving areas of interest, including earlier intervention, ultrasound for disease staging and presurgical mapping, and glucagon-like peptide-1 receptor agonists as adjunctive therapy in selected patients with obesity or metabolic comorbidity. Overall, optimal hidradenitis suppurativa surgery depends on individualized procedure selection, integration with medical therapy, and standardized outcome reporting to improve long-term patient care.
-
Assessment of preoperative gastric content with ultrasound in patients taking GLP-1 receptor agonists: an observational, multicenter, cross-sectional study.
No abstract available in PubMed.
-
Beyond Weight Loss: A Scoping Review and Thematic Analysis of GLP-1 Receptor Agonists Across the Neurosurgical Landscape.
AI summary of the abstract, unverified
- Scoping review (PRISMA-ScR) of 48 included studies from 1,342 screened, mostly US-based and retrospective (43/48).
- Included studies examined GLP-1 receptor agonist exposure in adults with spinal, intracranial, or cerebrovascular disease, grouped into three themes.
- Spinal fusion studies repeatedly linked perioperative exposure to lower pseudarthrosis, though some reported more postoperative complications; IIH studies linked it to lower papilledema and shunt placement.
- The authors judge benefit signals most consistent in spinal fusion and IIH, but adverse effects and database overlap limit causal inference, and they call for prospective trials.
Original abstract (PubMed)
BACKGROUND: GLP-1 receptor agonists (GLP-1RAs) are increasingly used for diabetes and obesity. Literature spans spinal fusion, idiopathic intracranial hypertension (IIH), and cerebrovascular disease, but has not been systematically mapped. We aimed to map literature on GLP-1RA exposure in neurosurgical landscapes by characterizing study design, drug class, disease-specific outcomes, and safety considerations. METHODS: This scoping review was conducted per the PRISMA-ScR guideline. Eligible studies reported GLP-1RA exposure in adults with spinal, intracranial, or cerebrovascular disease, recording clinical, perioperative, or imaging outcomes. Two reviewers screened independently with third-reviewer adjudication. Extracted variables included country, design, agent, timing, indication, neurosurgical and metabolic outcomes, and adverse events. RESULTS: Of 1342, 48 were included, predominantly from the United States (US) (34/48, 71%). Most were retrospective (43/48, 90%); 31/48 (65%) used propensity score matching; 5/48 (10%) were randomized. Three themes dominated: spinal fusion (24/48, 50%), IIH and cerebrospinal fluid (CSF) dynamics (14/48, 29%), and cerebrovascular and neurointerventional disease (10/48, 21%). In spinal fusion, perioperative GLP-1RA exposure was repeatedly associated with lower pseudarthrosis, although some studies reported increased postoperative complications. In IIH, GLP-1RAs were associated with lower papilledema, fewer CSF leaks, reduced acetazolamide requirement, and lower shunt placement. Cerebrovascular reports described lower intracerebral hemorrhage, subarachnoid hemorrhage, and post-stroke mortality, mostly in observational studies. CONCLUSIONS: GLP-1RA neurosurgical literature is dominated by US-based retrospective, propensity-matched analyses. Benefit signals are most consistent in spinal fusion and IIH, but perioperative adverse effects and overlap among database cohorts limit causal interpretation. Adequately powered prospective trials with standardized endpoints are needed to confirm results.
-
Urological manifestations in obesity.
AI summary of the abstract, unverified
- This narrative review summarizes recent evidence on obesity's effects across urology, including cancer, stone disease, incontinence, male reproductive health, kidney disease, and pediatric urology.
- It discusses SGLT2 inhibitors and GLP-1 receptor agonists for stone and infection risk, and weight loss or bariatric surgery for overactive bladder and stress incontinence.
- Findings are qualitative: obesity is described as offering a paradoxical survival benefit in renal cell carcinoma but driving aggressive prostate cancer, with no effect sizes given.
- The authors conclude that obesity's urological effects are heterogeneous and that weight loss and GLP-1 receptor agonists may help optimize and treat these conditions.
Original abstract (PubMed)
PURPOSE OF REVIEW: The global prevalence of obesity continues to rise, with effects ranging across urology. This review summarizes recent evidence on obesity and its impact on various urological conditions, including malignancy, infections, stone disease, functional urology and male reproductive health, chronic kidney disease, and pediatric urology, to guide comprehensive management in this population. RECENT FINDINGS: Obesity has a paradoxical survival benefit in patients with renal cell carcinoma, while its impact drives aggressive prostate cancer. Obesity increases kidney stone risk, with sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists showing divergent effects on lithogenesis and urinary tract infections. It is a modifiable risk factor for overactive bladder and stress urinary incontinence, both of which improve with weight loss/ bariatric surgery. Robotic surgery mitigates obesity-related perioperative risk. Hypogonadism secondary to obesity is a major reversible cause of male infertility. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) reverse metabolic hypogonadism and helps in slowing chronic kidney progression. Maternal and childhood obesity may impair testicular descent and can also increase the risk of nocturnal enuresis. SUMMARY: Obesity's urological effects are heterogeneous, paradoxical from pediatric to adults, mediated by insulin resistance, chronic inflammation, and hormonal dysregulation. Weight loss and the use of GLP-1 RA may offer a unique strategy for optimizing and treating urological conditions.
-
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
AI summary of the abstract, unverified
- This is a clinical framework paper, not an empirical study, and it draws on patient scenarios from common geriatric contexts rather than reported trial data.
- It addresses gut-hormone obesity drugs (GLP-1, GLP-1/GIP, and emerging triple agonists) used in older adults, with attention to sarcopenia, frailty, dehydration, aspiration, and weight regain.
- The authors argue that lean mass loss, malnutrition, and perioperative aspiration may matter more in older adults and need closer monitoring.
- They propose framing prescribing within the Geriatrics 5Ms and pairing treatment with resistance training, adequate protein, and functional monitoring.
Original abstract (PubMed)
Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.
-
Do Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of seven retrospective cohorts (28,525 patients) comparing lumbar fusion patients with and without preoperative GLP-1RA exposure.
- Six of the seven studies used propensity score matching or another matching strategy to balance the comparison groups.
- No significant association with reoperation or revision (OR 0.74, 95% CI 0.44-1.24; P = 0.25) or postoperative infection (OR 0.83, 95% CI 0.68-1.00; P = 0.05).
- The authors found no signal of increased postoperative risk and called for prospective studies with standardized exposure definitions and perioperative management protocols.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes, but lumbar fusion-specific associations with postoperative outcomes remain uncertain. OBJECTIVE: To evaluate the association between preoperative GLP-1RA exposure and surgical and postoperative outcomes in adults undergoing lumbar fusion. METHODS: PubMed, Embase, and the Cochrane Library were searched from inception through 14 May 2026. Comparative studies of adults undergoing lumbar fusion with and without preoperative GLP-1RA exposure were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I). Random-effects meta-analyses generated odds ratios with 95% confidence intervals. The protocol was prospectively registered in PROSPERO (CRD420261414637). RESULTS: Seven retrospective cohorts involving 28,525 patients were included; 6 used propensity score matching or another matching strategy. No statistically significant associations were observed between preoperative GLP-1RA exposure and reoperation or revision (OR: 0.74, 95% CI: 0.44-1.24; P = 0.25), postoperative infection (OR: 0.83, 95% CI: 0.68-1.00; P = 0.05), wound complications (OR: 0.86, 95% CI: 0.65-1.12; P = 0.26), or postoperative respiratory complications (OR: 1.08, 95% CI: 0.63-1.84; P = 0.69). Deep vein thrombosis, pulmonary embolism, and unplanned emergency department visits also did not differ significantly. All included studies were observational and predominantly used large administrative data sources. CONCLUSIONS: Across the evaluated outcomes, the available observational evidence did not identify a signal of increased postoperative risk associated with preoperative GLP-1RA exposure after lumbar fusion. Prospective studies with standardized exposure definitions and perioperative management protocols are warranted to confirm these findings and better define their clinical implications. CLINICAL RELEVANCE: Current observational evidence does not establish preoperative GLP-1RA exposure alone as an independent risk factor for adverse outcomes after lumbar fusion.
-
[Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review].
AI summary of the abstract, unverified
- Systematic review and random-effects meta-analysis of 27 studies, 13 of them in efficacy meta-analyses, searching PubMed, Web of Science and Embase to June 2026.
- Compared GLP-1 receptor agonist use by timing relative to bariatric surgery: preoperative, early postoperative (around 1 month), later postoperative (around 6 months), and rescue after weight regain or insufficient loss.
- Preoperative use raised preoperative weight loss (pooled SMD 0.52, 95% CI 0.25-0.79), but 12-month total body weight loss was 2.85 points lower (95% CI -4.35 to -1.36). Rescue use added 10.30 points (95% CI 6.40-14.20) across four RCTs.
- Authors conclude that rescue use has the strongest evidence, early postoperative use may add weight loss within the first year, and adverse events are mainly gastrointestinal with serious events uncommon.
Original abstract (PubMed)
Objective: To systematically evaluate the efficacy and safety of GLP-1 receptor agonists applied at different stages before and after bariatric surgery, and to compare the clinical benefits of preoperative use, early postoperative use, and rescue use after insufficient weight loss or weight regain according to medication timing. Methods: PubMed, Web of Science, and Embase via Ovid were searched from inception to June 20, 2026. A relatively strict three-concept search strategy was used, consisting of terms related to bariatric surgery, GLP-1 receptor agonists and specific drug names, and perioperative or weight-management scenarios. Searches were mainly restricted to title and abstract fields, and animal-only studies were excluded. Clinical studies involving patients who underwent metabolic and bariatric surgery and received GLP-1 receptor agonists before or after surgery were included. Studies were classified into three groups according to medication timing: preoperative use, early postoperative use, and rescue use after insufficient weight loss or weight regain. Mean difference or standardized mean difference was used for continuous variables, and odds ratio was used for categorical variables. Meta-analysis was performed using a random-effects model. Results: A total of 27 studies were included in the systematic review, including 10 studies on preoperative use, 4 on early postoperative use, and 13 on rescue use after insufficient weight loss or weight regain. Among them, 13 studies were included in efficacy meta-analyses. Preoperative use of GLP-1 receptor agonists improved preoperative weight loss, with a pooled SMD of 0.52 (95%CI: 0.25-0.79, I²=0%, P<0.05). However, when postoperative weight loss at 12 months was assessed using body weight at surgery as the baseline, the percentage of total body weight loss at 12 months was 2.85 percentage points lower in the preoperative medication group than in the non-medication group (95%CI: -4.35 to -1.36, I²=37.7%, P<0.05). Active addition of GLP-1 receptor agonists around 1 month after surgery increased the percentage of total body weight loss at 6 months by an additional 3.62 percentage points (95%CI: 1.88-5.37, I²=0%, P<0.05). Initiation of GLP-1 receptor agonists around 6 months after surgery resulted in an additional weight loss of 7.48 kg during subsequent follow-up compared with controls (95%CI: 5.35-9.60, I²=34.6%, P<0.05). For rescue therapy, four randomized controlled trials showed that GLP-1 receptor agonists resulted in an additional 10.30 percentage points of endpoint percentage weight loss compared with placebo or usual care (95%CI: 6.40-14.20, I²=89.2%, P<0.05). Regarding safety, among studies that clearly reported event numbers, the pooled incidences of nausea, constipation, diarrhea, and vomiting were 25.3%, 19.0%, 9.2%, and 8.6%, respectively. Serious adverse events were uncommon. Conclusion: GLP-1 receptor agonists have timing-specific value in the comprehensive management of metabolic and bariatric surgery. Preoperative use can increase preoperative weight loss but does not enhance postoperative weight loss when body weight at surgery is used as the baseline. Early postoperative use may further amplify weight-loss benefits within the first postoperative year. Rescue use after insufficient weight loss or weight regain is supported by the strongest evidence. In terms of safety, adverse events are mainly gastrointestinal, and serious adverse events are uncommon.
PubMed 42927970 Publisher (DOI) PubMed types: Systematic Review, Journal Article, Meta-Analysis, English Abstract -
The Impact of Glucagon-Like Peptide-1 Receptor Agonists on Post-Anesthetic Pulmonary and Gastrointestinal Adverse Events: A Target Trial Emulation Using Multinational Database.
AI summary of the abstract, unverified
- Target trial emulation using the TriNetX multinational database, with 21,948 propensity-matched adults aged 20 or older who underwent general anesthesia.
- Exposure was GLP-1 receptor agonist use before anesthesia versus no use, with one-month pulmonary and gastrointestinal adverse events analyzed by Cox regression.
- GLP-1 RA users had a lower risk of pulmonary adverse events (HR 0.682, 95% CI 0.496-0.938), with reduced respiratory failure and revisits also reported.
- Gastrointestinal adverse events were marginally higher with GLP-1 RA use (HR 1.034, 1.003-1.067); the authors describe this signal as modest.
Original abstract (PubMed)
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying, raising concerns about perioperative aspiration and postoperative complications. This target trial emulation aims to evaluate the association between the use of GLP-1 RAs and the risk of postoperative pulmonary and gastrointestinal adverse events in patients undergoing general anesthesia. METHODS: Data was utilized from the TriNetX Global Collaborative Network. The study analyzed data from January 1, 2023, to December 31, 2023. Patients aged 20 years or older who underwent general anesthesia were included. These patients were divided into two groups: those using GLP-1 RA and those who were not. Propensity score matching was used to balance baseline characteristics. The primary outcome measures were the incidence of pulmonary and gastrointestinal adverse events within one-month post-anesthesia. Hazard ratios were calculated using Cox proportional hazards regression models to estimate the risk of these adverse events associated with GLP-1 RA use. RESULTS: A total of 21,948 patients were included after matching. Patients who used GLP-1 RAs demonstrated a significantly lower risk of pulmonary adverse events (HR 0.682 [0.496-0.938]). Secondary outcomes further revealed a reduction in the risk of postoperative respiratory failure, as well as postoperative hospitalization and emergency department revisits. However, there was a marginally increased risk of gastrointestinal adverse events in the GLP-1 RA group (HR, 1.034 [1.003-1.067]). CONCLUSIONS: The use of GLP-1 RAs prior to general anesthesia was not associated with higher risk of pulmonary adverse events. A slight elevation in gastrointestinal risks was observed, although the signal remained modest.
-
Outcomes after Posterior Cervical Spine Surgery: A Matched Cohort Analysis and Comparison of GLP-1 Receptor Agonist Use and Bariatric Surgery in Patients with Type 2 Diabetes.
AI summary of the abstract, unverified
- Retrospective PearlDiver Mariner database study of patients with type 2 diabetes on metformin who underwent posterior cervical surgery from 2010 to 2023, using propensity-score matching.
- Preoperative GLP-1 receptor agonist users were compared with matched non-users and with patients who had prior bariatric surgery.
- GLP-1 users had lower odds of perioperative pneumonitis (OR 0.57; 95% CI 0.43-0.75; p<0.001) and of 90-day revision surgery (OR 0.33; 95% CI 0.29-0.36; p<0.001).
- Lower odds persisted for 2-year revision surgery and nutritional deficiency, and no significant differences were found versus the bariatric surgery cohort.
Original abstract (PubMed)
BACKGROUND CONTEXT: Obesity and diabetes can increase perioperative risk, especially in posterior cervical spine surgery. Bariatric surgery provides durable weight loss but carries surgical and nutritional risks, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are non-surgical alternatives that may optimize weight and metabolic status preoperatively. Evidence evaluating GLP-1 therapy in spine surgery is limited. PURPOSE: To evaluate associations between preoperative GLP-1 RA use and perioperative, short-term, and long-term complications following posterior cervical spine surgery in patients with type 2 diabetes, including comparisons to matched controls and patients with prior bariatric surgery. STUDY DESIGN: Retrospective database analysis. PATIENT SAMPLE: Patients with type 2 diabetes treated with metformin undergoing posterior cervical spine surgery between 2010 and 2023 were identified in the PearlDiver Mariner database. Patients were stratified into GLP-1 users, non-GLP-1 controls, and patients with prior bariatric surgery. OUTCOME MEASURES: Physiologic measures included perioperative outcomes and postoperative complications assessed at 90 days and 2 years, including pneumonitis, surgical site infection, revision surgery, readmission, nutritional deficiency, and other medical and surgical complications. METHODS: The PearlDiver Mariner database was queried for eligible patients. Propensity-score matching adjusted for baseline cohort differences. Outcomes included perioperative, 90-day, and 2-year complications, with BMI-stratified analyses conducted within the matched GLP-1 and control cohort. Benjamini-Hochberg false discovery rate correction was applied for multiple comparisons. RESULTS: GLP-1 users demonstrated lower odds of perioperative complications, including pneumonitis (OR 0.57; 95% CI 0.43-0.75; p <0.001). At 90 days, GLP-1 users experienced reduced odds of surgical site infection (OR 0.72; 95% CI 0.65-0.80; p <0.001), revision surgery (OR 0.33; 95% CI 0.29-0.36; p <0.001), readmission (OR 0.82; 95% CI 0.76-0.90; p <0.001), and other complications. At 2 years, GLP-1 users had lower odds of revision surgery (OR 0.31; 95% CI 0.28-0.34; p <0.001), nutritional deficiency (OR 0.62; 95% CI 0.59-0.66; p <0.001), and other complications. Exploratory BMI-stratified analyses suggested similar directional trends across overweight and obese patients. Comparisons to prior bariatric surgery patients showed no significant differences. CONCLUSIONS: Preoperative GLP-1 RA use was associated with reduced perioperative, short-term, and long-term complications following posterior cervical spine surgery in patients with type 2 diabetes. When compared with a matched bariatric surgery cohort, no significant differences in postoperative outcomes were observed. These findings should be interpreted in the context of potential residual confounding and support further prospective investigation of GLP-1 therapy as a strategy for preoperative metabolic optimization in posterior cervical spine surgery. CLASSIFICATIONS: Cervical Spine, Outcomes Research, Risk Factors, Perioperative Complications.
-
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.
AI summary of the abstract, unverified
- This is a narrative review of safety evidence for GLP-1 receptor agonists used in type 2 diabetes and obesity.
- Most safety evidence comes from pharmacovigilance databases, retrospective observational studies, and secondary trial analyses, which cannot establish causality.
- Gastrointestinal intolerance, modest heart rate increases, and gallbladder or biliary disease are the most consistently supported adverse effects, while pancreatitis risk remains debated.
- The authors judge the overall benefit-risk profile favorable and regard most other emerging concerns as hypothesis-generating rather than established toxicities.
Original abstract (PubMed)
PURPOSE OF REVIEW: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent one of the most significant therapeutic advances in the management of type 2 diabetes and obesity. As their indications have expanded to include cardiovascular and kidney disease, safety concerns involving multiple organ systems have received increasing attention. This narrative review examines the spectrum of adverse effects linked to GLP-1RAs and provides a clinically relevant platform for assessing their safe prescription. RECENT FINDINGS: Gastrointestinal intolerance, modest increases in heart rate, and a modest but reproducible increase in the risk of gallbladder and biliary disease represent the most consistently supported adverse effects of GLP-1RAs. A risk of pancreatitis is also considered to exist, although some studies have challenged this association. Conversely, correlations with neuropsychiatric and dermatological disorders, diabetic retinopathy, nonarteritic anterior ischemic optic neuropathy, perioperative aspiration, sexual and reproductive disturbances, sarcopenia, and malignancy remain controversial. Most available evidence derives from pharmacovigilance databases, retrospective observational studies, and secondary analyses of randomized trials, which are limited by reporting bias, residual confounding, and inability to establish causality. Heterogeneity in study design, statistical methodology, outcome definitions, and patient populations further complicates interpretation. Although several proposed adverse effects have biologically plausible mechanisms, prospective clinical validation remains limited. Notably, recent regulatory decisions, including the Food and Drug Administration (FDA)'s removal of the suicidality warning from GLP-1RA prescribing information, reflect the evolving nature of these safety assessments. The overall benefit-risk profile of GLP-1RAs is favorable. Most emerging safety concerns should currently be regarded as hypothesis-generating signals rather than established toxicities. Individualized risk assessment and appropriate clinical monitoring remain important as ongoing and future prospective studies further define the long-term safety of this rapidly expanding therapeutic class.
-
Impact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-Analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis following PRISMA guidelines, including 12 studies with 29,357 patients (10 pooled) in aesthetic and body-contouring surgery.
- Exposure was GLP-1 receptor agonist use compared with patients not taking these drugs, with outcomes including infection, dehiscence, healing, scarring, seroma, hematoma, and VTE.
- Pooled observational analyses linked GLP-1 RA use with higher risks of delayed wound healing and hypertrophic scarring; the abstract reports no effect sizes or CIs.
- A subgroup comparison found lower seroma rates in GLP-1 RA users than in patients with prior bariatric surgery, and the authors call for prospective studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly expanded in use for weight loss, resulting in a growing population of patients presenting for aesthetic and body-contouring procedures. Despite their increasing prevalence, the effects of GLP-1 RAs on postoperative wound healing and surgical outcomes remain poorly defined. METHODS: A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. PubMed, Embase, and Cochrane CENTRAL were searched from database inception through May 2026. Studies comparing postoperative outcomes in patients undergoing aesthetic and/or body-contouring surgery with and without GLP-1 RA exposure were included. Primary outcomes included infection, wound dehiscence, delayed wound healing, hypertrophic scarring, seroma, hematoma, and venous thromboembolism (VTE). Random-effects meta-analyses were performed using risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Twelve studies comprising 29,357 patients met inclusion criteria, with 10 studies included in quantitative synthesis. In pooled observational analyses, GLP-1 RA exposure was associated with increased risk of delayed wound healing and hypertrophic scarring. Subgroup analysis comparing GLP-1 RA users with patients who had previously undergone bariatric surgery demonstrated decreased seroma rates in the GLP-1 RA group. CONCLUSIONS: GLP-1 RA use in patients undergoing aesthetic and body-contouring surgery was associated in pooled observational analyses with increased risks of delayed wound healing and hypertrophic scarring, while GLP-1 RA use was associated with lower seroma rates in comparison with patients who have undergone bariatric surgery. As GLP-1 RA use become increasingly prevalent, further prospective studies are needed to clarify their perioperative effects and optimize patient selection and surgical outcomes.
-
Do Glucagon-Like Peptide-1 Receptor Agonists Sabotage Fat Grafts?: A Scoping Review of Glucagon-Like Peptide-1 Receptor Agonist Effects on Adipocyte Biology and Implications for Autologous Fat Transfer.
AI summary of the abstract, unverified
- This scoping review (PRISMA-ScR) synthesizes preclinical and clinical evidence on semaglutide, liraglutide, tirzepatide, and retatrutide effects on adipocytes and fat graft biology.
- The exposure is GLP-1 receptor agonist use, and the review maps its effects on adipocyte metabolism, adipose-derived stem cells, and revascularization onto models of fat graft take.
- The authors identify several potential interference points, including adipocyte browning, enhanced lipolysis, shifted stem cell differentiation, and altered inflammatory and angiogenic signaling, but no study has directly measured fat graft outcomes in patients on incretin therapies.
- The authors propose a research framework and preliminary perioperative considerations, which they explicitly label as hypothesis-generating rather than evidence-based guidance.
Original abstract (PubMed)
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management has created an unprecedented overlap with aesthetic surgery. Millions of patients experiencing GLP-1-mediated weight loss now present with facial volume depletion, soft tissue deflation, and contour irregularities; conditions for which autologous fat grafting remains the gold-standard solution. However, the fundamental biology of GLP-1 receptor agonism may be inherently antagonistic to the mechanisms upon which fat graft survival depends. This scoping review, conducted in accordance with the PRISMA extension for Scoping Reviews (PRISMA-ScR), synthesizes current preclinical and clinical evidence on the effects of semaglutide, liraglutide, tirzepatide, and the emerging triple agonist retatrutide on adipocyte metabolism, adipose-derived stem cell (ASC) function, and tissue revascularization, and maps these effects onto established models of fat graft take. We identify multiple potential interference points, including GLP-1-mediated adipocyte browning and thermogenic activation with upregulation of uncoupling protein 1 (UCP1) and mitochondrial uncoupling, enhanced lipolysis through adipose triglyceride lipase and hormone-sensitive lipase (HSL) upregulation, suppression of white adipogenic differentiation in ASCs with preferential commitment toward thermogenic beige lineages, and modulation of inflammatory and angiogenic signaling during the critical revascularization window. The growing off-label use of retatrutide in bodybuilding communities introduces additional concerns through glucagon receptor-mediated lipolysis and thermogenesis. Despite the strong mechanistic rationale, no clinical or preclinical studies have directly examined fat graft outcomes in patients receiving incretin-based therapies. We propose a framework for future investigation and offer preliminary, mechanism-based clinical considerations regarding perioperative GLP-1 RA management in fat transfer patients. These recommendations should be understood as hypothesis-generating rather than evidence-based guidelines. Level of Evidence: 1 (Therapeutic) For image description, please refer to the figure legend and surrounding text.
-
Thyroid Disease in the Era of Obesity and Glucagon-Like-Peptide-1 Agonists.
AI summary of the abstract, unverified
- The article addresses the relationship between thyroid disease and obesity, which the abstract describes as complex and bidirectional.
- It notes that both hypothyroidism and hyperthyroidism can influence body weight, and that body mass index is closely associated with thyroid dysfunction.
- It highlights a rise in thyroid cancer incidence alongside obesity prevalence over the past decade, and notes that the link between emerging weight-loss therapies and thyroid malignancy is still under investigation.
- It also covers perioperative and surgical considerations for patients undergoing thyroidectomy.
Original abstract (PubMed)
The thyroid gland plays a critical role in regulating metabolism. Dysfunctions in the thyroid gland are closely associated with alterations in body mass index. The relationship between thyroid disease and obesity is complex and bidirectional with hypothyroidism and hyperthyroidism influencing body weight. In the last decade, there has been an increase in the incidence of thyroid cancer as well as the prevalence of obesity. Emerging weight loss therapies and their potential association with thyroid malignancy remains an active area of investigation. Additionally, important perioperative and surgical considerations must be addressed in patients undergoing thyroidectomy.
-
GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.
AI summary of the abstract, unverified
- Systematic review of three randomized controlled trials including 168 adults with type 2 diabetes undergoing cardiac surgery.
- Compared liraglutide added to insulin with insulin alone or placebo, assessing perioperative glucose, variability, insulin adjustments, and hypoglycemia.
- Liraglutide was associated with lower glucose, reduced glycemic variability, and fewer insulin adjustments, with low hypoglycemia, though the abstract reports no effect sizes or p values.
- Nausea and vomiting were more frequent with liraglutide; the authors call the evidence preliminary and call for larger, standardized trials with long-term outcomes.
Original abstract (PubMed)
Perioperative hyperglycemia is common in patients with type 2 diabetes undergoing cardiac surgery and is linked to adverse outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer glucose-dependent insulinotropic effects and potential cardiac benefits, but their perioperative role remains uncertain. This review evaluated the efficacy and safety of GLP-1 RA therapy as an adjunct to insulin in this setting. Three electronic databases (PubMed, Cochrane, and Google Scholar) were searched for relevant articles up to October 2025. The primary endpoint was blood glucose levels during the perioperative period, while secondary endpoints included hypoglycemia incidence, total insulin requirement, time in target glucose range, and postoperative complications. Three randomized controlled trials (RCTs) including 168 patients with type 2 diabetes undergoing cardiac surgery were assessed. Perioperative use of liraglutide (subcutaneously in doses of 0.6-1.8 mg/day) was associated with preliminary evidence of improved glycemic control across preoperative, intraoperative, and early postoperative periods, including lower glucose levels, reduced glycemic variability, and fewer insulin adjustments, with a low incidence of hypoglycemia. However, heterogeneity in dosing, timing, and monitoring protocols across studies limits direct comparisons. Mild gastrointestinal adverse events, such as nausea and vomiting, were more frequent with liraglutide. One study reported exploratory immunometabolic effects in adipose tissue. Preliminary evidence from these heterogeneous studies suggests that adding liraglutide to insulin may improve perioperative glycemic control compared to insulin or placebo in patients with type 2 diabetes undergoing cardiac surgery. However, findings are limited by the small number of studies, methodological variability, and lack of long-term outcomes, necessitating larger, standardized trials.
-
Navigating Electroconvulsive Therapy in Patients on GLP-1 Receptor Agonists: Balancing Safety, Compliance, and Treatment Consistency: A Case Report.
AI summary of the abstract, unverified
- This case report describes one patient with refractory major depressive disorder taking tirzepatide, a GLP-1 receptor agonist, who received ECT.
- ECT and anesthesia leadership developed a novel pre-ECT fasting protocol for GLP-1 RA users, as an alternative to a 24-hour clear-liquid diet or frequent rapid sequence intubations.
- The patient completed 17 ECT treatments without complications.
- The authors frame the protocol as a way to balance aspiration safety, patient compliance, and treatment consistency.
Original abstract (PubMed)
Electroconvulsive therapy (ECT) is typically performed under general anesthesia without a secured airway, placing patients with retained gastric contents at increased risk of aspiration. As more patients present for ECT while taking GLP-1 receptor agonists, standard fasting requirements pose unique safety and patient-experience challenges. A 24-hour clear-liquid diet every other day is burdensome, while frequent rapid sequence intubations may prolong treatment and recovery. To address this, ECT and anesthesia leadership developed a novel pre-ECT fasting protocol for patients on GLP-1 RAs. We report a patient with refractory major depressive disorder on tirzepatide who successfully completed 17 ECT treatments without complications.
-
The gut-pancreas axis in chronic pancreatitis: Microbiota-endogenous GLP-1 interactions and candidate repair pathways.
AI summary of the abstract, unverified
- This is a narrative review combining chronic pancreatitis clinical data with cell, rodent, and non-CP human mechanistic studies, with no pooled quantitative analysis.
- It examines how intestinal barrier disruption raises lipopolysaccharide exposure and engages TLR4 signaling, and how microbial metabolites influence enteroendocrine L-cell GLP-1 secretion.
- Human CP studies of GLP-1 show heterogeneous responses, and no CP trial has yet linked microbiota-driven GLP-1 changes to disease progression.
- The authors propose a testable microbiota-metabolite-endogenous GLP-1 framework for CP, with causal direction and clinical relevance still requiring longitudinal validation.
Original abstract (PubMed)
Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder with limited disease-modifying options. Human CP studies report gut microbial and intestinal-barrier alterations, predominantly in cross-sectional cohorts. This review integrates CP-specific clinical and experimental observations with mechanistic evidence from cell, rodent, and non-CP human studies. Barrier disruption can increase lipopolysaccharide exposure and engage Toll-like receptor 4-associated inflammatory and fibrogenic signaling, whereas microbial and host-derived metabolites regulate enteroendocrine L-cell secretion through defined receptor-mediated and metabolic pathways. Human glucagon-like peptide-1 (GLP-1) studies in CP show heterogeneous responses, while CP trials have not yet connected microbiota-driven GLP-1 changes to disease progression. Evidence for direct pancreatic GLP-1 receptor (GLP-1R) signaling is strongest in β cells; reported immune, stellate-cell, and exocrine effects derive largely from preclinical or pharmacological studies and should not be equated with physiological endogenous GLP-1 exposure. CP-specific animal studies reported attenuated fibrosis or improved barrier and immune endpoints after microbiota-directed interventions, whereas limited human synbiotic trials reported improvements in selected gastrointestinal or perioperative outcomes but did not assess endogenous GLP-1, microbiome engraftment, pancreatic fibrosis, or disease progression. Together, these findings support a biologically coherent and testable microbiota-metabolite-endogenous GLP-1 framework for CP, with causal direction and clinical relevance requiring longitudinal validation. Translation requires microbiome-stratified CP trials incorporating functional microbiome and metabolite profiling; basal and meal-stimulated measurements of active and total GLP-1, together with peptide YY; prespecified clinical outcomes; mediation and treatment-by-biomarker analyses; and long-term safety assessment.
-
Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition.
AI summary of the abstract, unverified
- This mini-review synthesizes existing evidence on GLP-1 receptor agonists and dual incretin agonists in patients seeking aesthetic and reconstructive surgery.
- It covers perioperative risks, including delayed gastric emptying with possible aspiration, GI effects during dose escalation, lean mass loss, and weight regain after discontinuation.
- It reviews shifting anesthesia society guidance, from blanket preoperative withholding toward individualized risk stratification, and emerging body contouring outcome data in these users.
- The authors propose a framework for timing elective procedures around drug initiation, escalation, and maintenance, anchored in weight stability and symptom burden, plus a multidisciplinary endocrine-surgical-anesthetic algorithm.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists have transformed the management of obesity and type 2 diabetes and are rapidly reshaping the population seeking aesthetic surgery. By producing double-digit percentage weight loss, these agents expand eligibility for elective procedures while generating new patterns of skin redundancy, soft-tissue laxity, and facial volume depletion that drive demand for body contouring and facial rejuvenation. At the same time, incretin therapy introduces distinct perioperative considerations: delayed gastric emptying with possible pulmonary aspiration in symptomatic patients, gastrointestinal adverse effects that peak during dose escalation, loss of lean mass with rapid weight reduction, nutritional inadequacy during profound appetite suppression, and frequent weight regain after drug discontinuation, which threatens the durability of surgical results. This mini-review synthesizes current evidence on the mechanisms of GLP-1 RAs relevant to the reconstructive surgical patient, summarizes the evolving guidance from anesthesia societies, moving from blanket preoperative withholding to individualized risk stratification, reviews emerging outcome data on body contouring in GLP-1 RA users, and discusses body composition, sarcopenia risk, and nutritional optimization. We propose a pragmatic framework, anchored in weight stability and symptom burden, for timing elective aesthetic procedures relative to GLP-1 RA initiation, escalation, and maintenance, along with a multidisciplinary perioperative algorithm that links the endocrinologist, plastic surgeon, and anesthesiologist. As incretin-based pharmacotherapy expands globally, coordinated endocrine-surgical-anesthetic care will be essential to maximize safety, functional recovery, and patient satisfaction in the GLP-1 era.
-
Effects of GLP-1 receptor agonists on aesthetic surgery practice: A contemporary review.
AI summary of the abstract, unverified
- This contemporary narrative review combined a targeted PubMed/MEDLINE search from 2015 onward with manual reference screening, including cohorts, database analyses, surveys, and case reports.
- It examines how GLP-1 receptor agonists affect aesthetic surgery demand and outcomes across facial, breast, and body contouring procedures.
- The authors argue that facial volume loss and skin laxity ('Ozempic face') more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect.
- Body contouring outcomes are heterogeneous, with some studies reporting comparable complications and others noting delayed healing or dehiscence; the authors call for individualized decisions and prospective studies.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become increasingly relevant to aesthetic surgery because of the significant weight loss they provide in the treatment of type 2 diabetes mellitus and obesity. While these agents expand the pool of surgical candidates, they also raise new clinical questions related to rapid or substantial weight loss, including soft tissue volume loss, skin laxity, nutritional deficiencies, perioperative safety concerns, and the durability of aesthetic surgical outcomes. This contemporary narrative review evaluated the current implications of GLP-1 RAs in aesthetic plastic surgery practice. A targeted PubMed/MEDLINE search covering January 2015 through August 2026 was supplemented by manual reference screening. Retrospective cohorts, database analyses, prospective observational studies, systematic reviews, survey studies, case reports, and selected guidance or opinion articles were evaluated. Current literature indicates increasing demand for facial aesthetic, breast aesthetic, and body contouring procedures among patients using GLP-1 RAs. The facial volume loss and skin laxity popularly described as "Ozempic face" more plausibly reflect rapid or substantial weight loss than a proven drug-specific facial effect. Although the breast surgery literature remains limited, upper-pole volume loss, ptosis, reduced soft tissue support, and healing problems along high-tension closure lines are noteworthy. Outcomes in body contouring surgery are heterogeneous: While some studies report comparable complication rates, others emphasize delayed wound healing, wound dehiscence, altered scar behavior, or nutrition-related risks. Surgical timing, weight stabilization, nutritional balance, and individualized perioperative aspiration-risk assessment are key areas of evaluation. GLP-1 RA use should be considered neither an absolute advantage nor an automatic contraindication in aesthetic surgery. Direct pharmacologic effects often cannot be separated from the consequences of weight loss or baseline metabolic risk. Surgical decision-making should be individualized based on weight stability, metabolic optimization, nutritional status, history of bariatric surgery, psychological adaptation, and procedure-specific risks. Current evidence is promising but heterogeneous, and prospective studies are needed to clarify long-term aesthetic outcomes and procedure-specific risks.
-
Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists.
AI summary of the abstract, unverified
- This is a narrative review that synthesizes evolving evidence and international guidance on perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors.
- GLP-1 receptor agonists slow gastric emptying, raising aspiration concern, but recent large-scale data reportedly show no increase in clinically significant aspiration under modern anesthetic practice.
- For GLP-1 receptor agonists, the review supports an individualized, risk-based approach with targeted mitigation for higher-risk patients rather than routine cessation.
- Perioperative guidance for SGLT2 inhibitors has converged toward preoperative discontinuation to reduce euglycemic diabetic ketoacidosis risk, and the authors emphasize anesthesiologists coordinating care that balances metabolic safety with cardiovascular and renal benefit.
Original abstract (PubMed)
The widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose linked transporter-2 (SGLT2) inhibitors have substantially improved glycemic control and cardiometabolic outcomes in patients with diabetes and related conditions. However, their increasing perioperative use has introduced important safety considerations for anesthesiologists. GLP-1RAs are associated with delayed gastric emptying, raising concerns regarding aspiration risk, while SGLT2 inhibitors have been linked to euglycemic diabetic ketoacidosis (EDKA), particularly in the context of surgical stress and perioperative fasting. This review synthesizes evolving evidence and international guidance to inform contemporary perioperative management of these agents. For GLP-1RAs, early recommendations advocating routine preoperative cessation have been increasingly challenged by recent large-scale outcome data demonstrating no increase in clinically significant aspiration under modern anesthetic practice, supporting an individualized, risk-based approach with targeted mitigation strategies for higher-risk patients. In contrast, perioperative guidance for SGLT2 inhibitors has converged toward preoperative discontinuation to minimize EDKA risk. The review highlights the central role of anesthesiologists in coordinating multidisciplinary, patient-centered care that balances metabolic safety with preservation of established cardiovascular and renal benefits.
-
Perioperative management of patients taking GLP-1 receptor agonists: A comparative review of international clinical guidelines.
AI summary of the abstract, unverified
- This systematic review appraised five perioperative GLP-1 receptor agonist guidelines published 2023 to 2026 using the AGREE-REX framework and reviewed their underlying primary studies.
- The review compared how the guidelines handle continuing these drugs before anesthesia, fasting modification, symptom-based risk stratification, and gastric ultrasound.
- Four of five guidelines recommend continuing the drug with structured fasting modification, replacing the 2023 ASA cessation policy, though fasting protocols still differ substantially.
- The authors conclude that guidelines share a direction but remain contested in operational details, and that prospective data on aspiration and glycemic events are urgently needed.
Original abstract (PubMed)
GLP-1 receptor agonists (GLP-1 RAs) are now routinely encountered in preoperative assessment. Their effect on gastric emptying raises concern about pulmonary aspiration risk during anesthesia. Five major professional bodies have published perioperative guidance since 2023, reaching divergent conclusions on four clinically important questions. A systematic search of PubMed, MEDLINE, Embase, professional society websites, and grey literature was conducted for perioperative GLP-1 RA guidelines published between January 2023 and March 2026. Five documents met eligibility criteria. Each was independently appraised by two reviewers using the AGREE-REX framework, and primary studies underpinning the guidelines were reviewed for four pre-specified clinical questions. Four of five guidelines now recommend drug continuation with structured fasting modification, superseding the 2023 American Society of Anesthesiologists (ASA) cessation policy. Fasting protocols diverge substantially: SPAQI 2025 uniquely distinguishes high-calorie from low-calorie liquids. Three of five documents explicitly state that absence of gastrointestinal symptoms cannot be relied upon for risk stratification. All five guidelines endorse gastric ultrasound but none define validated decision thresholds. AGREE-REX appraisal identified the Anesthetists of Great Britain and Ireland (AAGBI)/Royal College of Anesthetists (RCoA) 2025 statement as having the broadest multidisciplinary representation and the most transparent process; Society for Perioperative Assessment and Quality Improvement (SPAQI) 2025 had the most rigorous evidence base but the most complex implementation requirements. Endocrinologist and obesity medicine representation is absent from most authoring groups, and the recommendations reflect this. International guidelines share a direction, to continue with modified fasting, but the operational details remain contested. The clinical risks of incomplete gastric emptying, hypoglycemia in insulin-dependent patients, and the absence of validated gastric ultrasound decision thresholds are not yet adequately reflected in most guidance. Prospective outcome data capturing aspiration events and glycemic complications remain urgently needed.
-
Gastric residual volume in patients with obesity receiving GLP-1 receptor agonists: A comparative gastric ultrasound pilot study.
AI summary of the abstract, unverified
- Comparative cross-sectional pilot study of patients with obesity, comparing those taking GLP-1 receptor agonists with nonusers scheduled for surgery.
- Gastric point-of-care ultrasound in supine and lateral positions, with antral cross-sectional area and residual volume estimated by validated mathematical models.
- GLP-1 receptor agonist users had higher estimated gastric residual volume, and a higher proportion met ultrasound criteria for a full stomach; the abstract reports no effect sizes or p values.
- The authors conclude GLP-1 receptor agonist use was associated with a larger antrum and greater gastric contents, suggesting higher estimated aspiration risk, and propose ultrasound to guide individualized aspiration precautions.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) enhance insulin secretion, suppress glucagon release, promote satiety, and may slow gastric emptying. Introduced in 2005 for the treatment of type 2 diabetes and obesity, these agents have prompted interest in assessing delayed gastric emptying as a potential biomarker to predict treatment response and to guide decisions regarding long-term therapy. Point-of-care gastric ultrasound (POCUS) offers a bedside method to assess gastric contents. OBJECTIVES: To compare gastric residual volume (GRV) on gastric ultrasound among patients with obesity receiving GLP-1 RAs and nonusers and those with prior weight loss surgeries. METHODS: In this comparative cross-sectional pilot study, gastric POCUS was done on patients with obesity who took GLP-1 RAs and other patients with obesity with no history of taking GLP-1 RAs prior to surgery in the supine and lateral decubitus positions. Antral cross-sectional area and GRV were measured using validated mathematical models. RESULTS: Patients receiving GLP-1 RAs demonstrated higher estimated GRV compared with nonusers. A higher proportion of GLP-1 RA users met ultrasound criteria for a full stomach. CONCLUSION: Among patients with obesity, GLP-1 RA therapy was associated with enlargement of the gastric antrum, increased gastric volume, and greater residual gastric contents, leading to an elevated estimated risk of aspiration. This increased risk is primarily determined by gastric ultrasound findings rather than patient characteristics, comorbidities, or duration of treatment. Gastric ultrasound may support individualized perioperative decision-making regarding aspiration precautions.
-
Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
AI summary of the abstract, unverified
- Narrative expert review pooling RCTs, observational studies, meta-analyses, and pharmacovigilance data on GI adverse effects of GLP-1 and dual GIP/GLP-1 receptor agonists.
- Nausea, vomiting, diarrhea, and constipation are described as class effects in about 30%-50% of patients, mostly during initiation and dose escalation, and usually mild to moderate.
- Randomized data show no class-level excess acute pancreatitis risk, while cholelithiasis is a probable class association that is largely mediated by weight loss.
- The authors conclude GI events are predictable and manageable, and pipeline agents (retatrutide, survodutide, cagrilintide-semaglutide) show a similar profile, though evidence is limited.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation. METHODS: This narrative expert review synthesizes evidence from randomized controlled trials, observational studies, meta-analyses, and pharmacovigilance data to characterize the incidence, mechanisms, and clinical implications of GI adverse effects across approved agents and late-stage pipeline therapies. RESULTS: Nausea, vomiting, diarrhea, and constipation are established class effects, occurring in approximately 30%-50% of patients, typically during initiation and dose escalation. These events are generally mild to moderate and manageable with dose titration and dietary modification. Mechanisms include delayed gastric emptying, central activation of emetic pathways, altered intestinal motility, and physiologic effects of rapid weight loss itself. Randomized trial data are reassuring for acute pancreatitis, with no class-level excess risk demonstrated; pharmacovigilance signals are most plausibly explained by diagnostic misclassification rather than true causal risk. Cholelithiasis shows a probable class-level association, substantially mediated by weight loss rather than direct receptor signaling. Peri-procedural data show increased residual gastric volume without confirmed aspiration events. Preliminary data on late-stage pipeline agents (retatrutide, survodutide, and cagrilintide-semaglutide) suggest a similar GI adverse event profile to approved agents, though evidence remains largely limited. CONCLUSION: GI adverse events with GLP-1-based therapies are predictable and manageable. A proactive, patient-centered approach is essential to optimize adherence, safety, and clinical outcomes as newer agents expand the therapeutic landscape.
-
GLP-1 agonists before endoscopy: separating fact from fiction.
AI summary of the abstract, unverified
- This narrative review summarizes the physiology of GLP-1 agonist-delayed gastric emptying and recent literature on residual gastric volume before sedated endoscopy.
- The review compares holding the GLP-1 agonist dose with continuing it alongside 24 hours of clear liquids as preventive strategies.
- Both approaches are described as effective, with a trend favoring continuation plus clear liquids, and point-of-care ultrasound is described as highly accurate for detecting residual gastric volume in experienced hands.
- The authors conclude that recent studies have considerably improved understanding of the pathophysiology and risk of residual gastric volume with these drugs.
Original abstract (PubMed)
PURPOSE OF REVIEW: Glucagon-1 receptor agonists (GLP-1A) delay gastric emptying, which has raised concerns about heightened risk of increased residual gastric volume (RGV) despite appropriate fasting measures. RGV could increase risk of pulmonary aspiration during sedated procedures like upper endoscopy. The purpose of this review is to summarize literature on pathophysiology of delayed gastric emptying, and to highlight recent publications on risk of RGV and preventive strategies. RECENT FINDINGS: GLP-1A delay gastric emptying via vagally mediated pathways; with long-term use this delay in gastric emptying is attenuated. GLP-1A significantly increases risk of RGV. Holding a dose of GLP-1A or continuing the medication with 24 h of clear liquids beforehand are both effective strategies. There is a trend towards greater effectiveness with the latter approach. In experienced hands, point of care ultrasound (POCUS) is highly accurate at identifying RGV before sedation. SUMMARY: Recent studies have considerably enhanced our understanding of the pathophysiology and risk of RGV with GLP1A.
-
The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.
AI summary of the abstract, unverified
- A retrospective case-control study at a large tertiary health system compared GLP1-RA users with matched diabetics off GLP1-RAs undergoing outpatient EGD and/or colonoscopy from 2018 to 2023.
- Cases never held their GLP1-RAs, and the authors also examined a 24-hour preprocedural liquid diet plus bowel preparation as a way to reduce gastric retention risk.
- Gastric food retention was higher in cases than controls (4.7% vs 1%, P=0.03), while inadequate bowel preparation was identical at 16.5% in both groups.
- The authors conclude GLP1-RAs raise gastric food retention independent of diabetes, and that a 24-hour liquid diet with bowel preparation appears to offset that risk.
Original abstract (PubMed)
OBJECTIVES: While glucagon-like peptide 1 receptor agonists (GLP1-RAs) increase the risk of gastric food retention (GFR) and inadequate bowel preparation (IBP), the confounding role of diabetes mellitus is still questioned. Here, we compare the outcomes of endoscopic procedures in patients on GLP1-RAs versus matched diabetics off GLP1-RAs, while also assessing the role of a 24-hour preprocedural liquid diet and bowel preparation in mitigating this risk. METHODS: A retrospective case-control study of patients 18 years or older on GLP1-RAs versus matched diabetics off GLP1-RAs who underwent outpatient EGD and/or colonoscopy between January 2018 and June 2023. The case group never held their GLP1-RAs. Primary outcomes were the risk of GFR and IBP. Secondary outcomes included the rates of aborted procedures, periprocedural aspiration, and the risk of GFR in GLP1-RAs who underwent EGD alone versus EGD + colonoscopy. RESULTS: Our study included 417 EGDs (212 cases vs. 205 controls) and 637 colonoscopies (303 cases vs. 334 controls). There was no significant difference in age, gender, BMI, and preprocedural A1c% between groups. The GFR was significantly higher in the cases compared with controls (4.7% vs. 1%, P =0.03), whereas there was no difference in IBP (16.5% vs. 16.5%, P =1). There was no significant difference in EGD abortion (1.9% vs. 0.5%, P =0.3) or colonoscopy abortion (7.6% vs. 6%, P =0.4) between cases and controls. None of the patients in both groups had periprocedural aspiration or conversion to general anesthesia. Compared with EGD alone (n=105), cases who underwent a concomitant colonoscopy (n=107) had a significantly lower risk of GFR (9.5% vs. 0%, P <0.01). DISCUSSION: GLP1-RAs increase the risk of GFR independent of concomitant diabetes but not the rate of IBP. The absolute procedural risks associated with GLP1-RAs are minimal. A 24-hour liquid diet combined with bowel preparation appears to offset the risk of GFR associated with GLP1-RAs.
-
Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract.
AI summary of the abstract, unverified
- This review examines how bariatric surgery and medical weight-loss therapies affect the upper aerodigestive tract, covering mechanical, metabolic, inflammatory, and gastrointestinal effects.
- Evidence is strongest for obstructive sleep apnea, where substantial weight reduction improves severity but does not reliably lead to remission.
- Emerging data suggest possible benefits for chronic rhinosinusitis and some voice outcomes, alongside risks including reflux, chronic cough, delayed gastric emptying, and patulous Eustachian tube dysfunction.
- The authors advise otolaryngologists to account for weight-loss method, magnitude, rate, and durability in evaluation, counseling, and perioperative planning.
Original abstract (PubMed)
Obesity and intentional weight loss increasingly influence otolaryngologic disease through mechanical, metabolic, inflammatory, gastrointestinal, and regional soft-tissue effects. This review examines how bariatric surgery and contemporary medical weight-loss therapies affect the upper aerodigestive tract. Evidence is strongest for obstructive sleep apnea, in which substantial weight reduction improves disease severity but does not ensure remission. Emerging data suggest potential benefits for chronic rhinosinusitis and selected voice outcomes, alongside risks such as procedure-specific reflux, chronic cough, delayed gastric emptying, nutritional complications, and patulous Eustachian tube dysfunction. Otolaryngologists should incorporate the weight-loss method, magnitude, rate, and durability into evaluation, counseling, and perioperative planning.
-
Perioperative Safety Considerations and Surgical Outcomes Associated With GLP-1-Based Therapies: A Systematic Review.
AI summary of the abstract, unverified
- This PRISMA-guided, PROSPERO-registered systematic review included 16 studies: seven observational studies and nine case reports or case series in adults undergoing sedation or general anesthesia.
- The review examined perioperative gastric physiology and safety outcomes in patients taking GLP-1 receptor agonists, with semaglutide singled out in the observational data.
- Observational studies linked GLP-1 RA use to more residual gastric contents or delayed emptying despite standard fasting, while clinically apparent aspiration was uncommon and mainly described in case reports.
- Larger observational studies showed no clear increase in aspiration or broader complications, and retained gastric contents changed anesthetic plans or postponed elective cases in several reports.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the management of type 2 diabetes mellitus and obesity. Their effects on gastric emptying have raised concerns in the perioperative setting, where standard fasting protocols are used to reduce aspiration risk. However, the clinical significance of altered gastric physiology and its implications for perioperative management remain uncertain. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD420261289189). A comprehensive literature search identified studies evaluating perioperative gastric physiology and procedural safety outcomes associated with GLP-1 RA use in adults undergoing procedures requiring sedation or general anesthesia. Outcomes included delayed gastric emptying, residual gastric contents, aspiration or regurgitation events, and perioperative management adaptations. Sixteen studies met the inclusion criteria, comprising seven observational studies and nine case reports or case series. Observational evidence demonstrated an association between GLP-1 RA use, particularly semaglutide, and increased residual gastric contents or delayed gastric emptying despite adherence to standard fasting protocols. These findings were identified primarily through gastric ultrasound and endoscopic assessment. In contrast, clinically apparent aspiration or regurgitation events were uncommon and were reported predominantly in case-based literature. Larger observational studies did not demonstrate a clear increase in aspiration or broader perioperative complications. Identification of retained gastric contents also influenced clinical management in several reports, resulting in changes to anesthetic planning, additional gastric assessment, or postponement of elective procedures. GLP-1 RA therapy is associated with alterations in gastric physiology that may challenge the assumptions underlying standard preoperative fasting protocols. Although increased residual gastric contents are consistently reported, current evidence does not establish a corresponding increase in clinically significant aspiration events. Individualized preoperative risk assessment, including consideration of medication exposure and selective use of gastric ultrasound, may assist perioperative decision-making. Further prospective studies are needed to quantify aspiration risk and establish evidence-based perioperative management strategies.
-
Preoperative Glucagon-like Peptide-1 Receptor Agonists and Postoperative Outcomes: An Observational Analysis.
AI summary of the abstract, unverified
- An observational analysis of TriNetX electronic health record data (2013–2023) compared adults with type 2 diabetes who had anesthesia, propensity-matched 1:1.
- Preoperative GLP-1 receptor agonist use was compared with metformin, SGLT2 inhibitors, or DPP4 inhibitors, with outcomes assessed over 14 days after surgery.
- Versus metformin, GLP-1 RA use was associated with lower 14-day mortality (0.98% vs 2.20%; RR 0.44, 95% CI 0.31 to 0.64; Padj 0.0002).
- Versus DPP4 inhibitors, GLP-1 RAs were linked to lower mortality and bacterial pneumonia, while the SGLT2 inhibitor comparison for major adverse cardiovascular events was not significant.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes management with demonstrated benefits on glycemic control, cardiac outcomes, and weight reduction, but further study is needed to establish the impact of GLP-1 RAs on perioperative outcomes. METHODS: The authors conducted an observational analysis with data between June 1, 2013, to June 1, 2023, using an electronic health record database (TriNetX Research Network) before the 2023 American Society of Anesthesiologists guidance to hold GLP-1 RAs preoperatively. Adult surgical patients with type 2 diabetes mellitus having anesthesia were propensity-score-matched 1:1 by surgery type, patient characteristics, diabetic biomarkers, and risk factors for postoperative morbidity. The study compared GLP-1 RA use with (1) metformin, (2) sodium-glucose cotransporter 2 inhibitors, or (3) dipeptidyl peptidase-4 inhibitors (DPP4i). Each group did not have concomitant use of the comparator. Outcomes were 14-day postoperative mortality, aspiration pneumonitis, bacterial pneumonia, emergency intubation, acute kidney injury, stroke, acute myocardial infarction, and major adverse cardiovascular events as defined by a composite of mortality, myocardial infarction, or stroke. RESULTS: Preoperative GLP-1 RA use was associated with reduced mortality (0.98% vs . 2.20%; risk ratio [RR], 0.44; 95% CI, 0.31 to 0.64; Padj = 0.0002) when compared with metformin use. Compared with sodium-glucose cotransporter 2 inhibitors, GLP-1 RAs were associated with numerical difference in major adverse cardiovascular events (3.86% vs . 5.03%; RR, 0.77; 95% CI, 0.60 to 0.98; Padj = 0.13). When compared with DPP4is, GLP-1 RAs were associated with decreased postoperative mortality (1.84% vs . 2.89%; RR, 0.63; 95% CI, 0.45 to 0.89; Padj = 0.04) and bacterial pneumonia (0.85% vs . 1.80%; RR, 0.47; 95% CI, 0.29 to 0.76; Padj = 0.02). CONCLUSIONS: Preoperative GLP-1 RA use was associated with lower short-term postoperative mortality and reduced morbidity compared with metformin and DPP4is, and no increased aspiration risk compared with any other drug class. Although these findings suggest perioperative benefits of GLP-1 RAs, confirmation in prospective studies is needed to guide evidence-based management strategies.
-
Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.
AI summary of the abstract, unverified
- This narrative review covers metabolic-inflammatory pathways in hidradenitis suppurativa, including insulin/IGF-1 signaling, mTORC1 activation, adipokines, and gut-skin interactions.
- It evaluates evidence on GLP-1 receptor agonists, dual incretin agonists, and other metabolic interventions such as metformin in HS.
- The authors judge GLP-1 receptor agonists a possible adjunctive therapy for selected patients with HS and obesity or metabolic syndrome, but the abstract reports no quantitative results.
- They note that the existing evidence is mainly observational and confounded by concomitant therapies, so randomized trials with dermatologic and metabolic endpoints are needed.
Original abstract (PubMed)
INTRODUCTION: Hidradenitis suppurativa (HS) is increasingly recognized as a systemic immunometabolic disease associated with obesity, insulin resistance, and metabolic syndrome (MetS). A metabolically unhealthy lean phenotype indicates that metabolic dysfunction and chronic low-grade inflammation may occur independently of increased body mass index (BMI) in patients with HS. Reduced effectiveness of biologic therapies in patients with obesity further supports targeting the upstream metabolic drivers of inflammation. AREAS COVERED: This review outlines metabolic-inflammatory pathways proposed to contribute to HS, including insulin/insulin-like growth factor 1 (IGF-1) signaling, mechanistic target of rapamycin complex 1 (mTORC1) overactivation, adipokine dysregulation, and gut-skin interactions. Building on this framework, this review evaluates evidence on glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual incretin agonists, and other metabolic interventions, including metformin is evaluated. EXPERT OPINION: GLP-1RAs may serve as adjunctive metabolic therapies for selected patients with HS and obesity or MetS. By promoting weight loss and metabolic improvement, they may reduce systemic inflammation, perioperative risk, and improve responses to weight-based biologics. However, current evidence remains mainly observational and is confounded by concomitant therapies. Randomized controlled trials using well-defined dermatological and metabolic endpoints are needed before routine implementation.
-
Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation.
AI summary of the abstract, unverified
- This is a narrative review of the literature on strategies to optimize outcomes in patients having bariatric and body contouring surgery, with no pooled sample.
- It examines exercise preconditioning, nutritional supplementation, psychological support, and modification of wound healing risk factors as a longitudinal prehabilitation approach.
- The authors report that these measures may improve cardiorespiratory fitness, and that prehabilitation may also support weight-loss durability, body composition, and candidacy for body contouring.
- They conclude that prehabilitation may optimize these patients, but standardized protocols and proof of effectiveness in this population still need further research.
Original abstract (PubMed)
BACKGROUND: Rates of obesity and diabetes are increasing in the United States, accompanied by greater use of bariatric surgery and pharmacologic therapies, including glucagon-like peptide-1 receptor agonists and glucose-dependent insulinotropic polypeptide-based agents. Although massive weight loss may improve glycemic control and blood pressure, patients seeking body contouring surgery remain medically complex. Reduced fat-free mass associated with weight-loss pharmacotherapy and the high incidence of wound healing complications after excess skin resection present additional perioperative challenges. METHODS: We reviewed the growing literature on strategies to optimize outcomes after body contouring surgery, with particular attention to exercise preconditioning, nutritional supplementation, psychological support, and modification of established wound healing risk factors. RESULTS: Current evidence suggests that supplementing conventional risk-factor modification with exercise preconditioning, nutritional support, and psychological interventions improve the cardiorespiratory fitness of weight loss patients. Comprehensive prehabilitation initiated before bariatric surgery and continued throughout weight loss and subsequent plastic surgical treatment may also improve weight-loss durability, body composition, and candidacy for body contouring. CONCLUSIONS: Prehabilitation may provide a comprehensive, longitudinal approach to optimizing patients undergoing bariatric and body contouring surgery. Integrating exercise, nutritional supplementation, psychological support, and traditional risk-factor modification has the potential to improve surgical candidacy, perioperative health, and postoperative outcomes. Further research is needed to define standardized protocols and determine their effectiveness in this population.
-
Prehabilitation for Aesthetic Surgery: An Evidence-based Guide.
AI summary of the abstract, unverified
- This narrative review covers medical management, nutrition, substance cessation, weight, and psychological factors in aesthetic surgery, with added detail for rhytidectomy and rhinoplasty.
- It notes that malnutrition, diabetes, and tobacco use are linked to adverse surgical outcomes, though aesthetic-specific recommendations for these are lacking.
- The authors advise addressing hypertension before rhytidectomy and obstructive sleep apnea before rhinoplasty, and considering psychological concerns from the initial consultation.
- They also state that GLP-1 agonists have changed the aesthetic landscape and that patients should be counseled on their use using the latest evidence.
Original abstract (PubMed)
BACKGROUND: Despite the growing number of aesthetic plastic surgery procedures performed annually and increasing emphasis placed on surgical prehabilitation to improve postoperative outcomes, there is not yet a standardized guide for patients undergoing these aesthetic procedures. The aim of this review is to identify the major components of prehabilitation for aesthetic surgery to decrease the risk of perioperative complications and facilitate a smooth recovery process. METHODS: A narrative literature review was conducted for common aesthetic surgery topics, including medical management, nutrition and diet, substance use cessation, weight management, and psychological factors surrounding aesthetic surgery. Additional information was included for specific procedures with existing robust evidence, including rhytidectomy and rhinoplasty. RESULTS: There are strong existing ties between established risk factors such as malnutrition, diabetes, and tobacco use with adverse surgical outcomes, though these topics lack aesthetic surgery-specific recommendations. Hypertension and obstructive sleep apnea should be addressed and managed for patients seeking rhytidectomy or rhinoplasty, respectively. Psychological concerns are pervasive among aesthetic surgery patients and should be kept in consideration beginning at the initial consultation. Emerging players, such as glucagon-like peptide-1 agonists, have shifted the aesthetic landscape, and patients should be counseled on their use with the latest evidence-based recommendations. CONCLUSIONS: Prehabilitation in aesthetic surgery should address known risk factors early on in surgical planning to prevent poor outcomes and should be tailored to each patient. There are certain measures, outlined here, that patients undergoing aesthetic surgery can take to prepare themselves for improved surgical outcomes and recovery.
-
GLP-1 receptor agonists and weight-loss strategies for individuals with obesity and hip or knee osteoarthritis: a scoping review.
AI summary of the abstract, unverified
- This PRISMA-ScR scoping review of 199 studies (2010 to August 2025) mapped weight-loss strategies in adults with obesity and hip or knee osteoarthritis.
- Of the included studies, 36 (18.1%) directly assessed GLP-1 receptor agonists, and only 14 of those reported original data.
- Most GLP-1 studies (29/36) were published in 2024–2025, and 19/36 were level 5 evidence; knee data showed weight loss and pain/function gains, while hip data were sparse.
- The authors call GLP-1 receptor agonists a promising adjunct and advise using them within supervised, multimodal musculoskeletal care rather than as standalone weight-loss agents.
Original abstract (PubMed)
OBJECTIVE: To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity. DESIGN: Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O'Malley. DATA SOURCES: PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025). ELIGIBILITY CRITERIA: Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs. RESULTS: Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations. CONCLUSION: GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.
-
[GLP-1 Receptor Agonists in Urology and Andrology: Indications, Opportunities and Clinically Relevant Adverse Effects].
AI summary of the abstract, unverified
- Narrative review of a PubMed search (2020–2026) covering GLP-1 receptor agonists across urology and andrology domains.
- Agents discussed include semaglutide, liraglutide and tirzepatide, with domains spanning erectile dysfunction, hypogonadism, fertility, nephroprotection, prostate cancer and bladder symptoms.
- Benefits include better testosterone and erectile function in obesity-related hypogonadism, while semaglutide showed a 4.5-fold higher new-onset erectile dysfunction risk in non-diabetic obese men.
- The authors call these agents both an opportunity and a challenge, recommend systematic monitoring, and call for prospective controlled trials with urological endpoints.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have evolved rapidly from an antidiabetic drug class into one of the most influential pharmacological groups in internal medicine. The approved agents - semaglutide, liraglutide and the dual GIP/GLP-1 agonist tirzepatide - achieve weight reductions of up to 22% of body weight. The close pathophysiological link between obesity, metabolic syndrome and urological-andrological disease creates direct clinical relevance for urology.This narrative review summarises a systematic PubMed search (2020-2026) covering erectile dysfunction, hypogonadism, male fertility, nephroprotection, prostate cancer, lower urinary tract symptoms and perioperative considerations in the context of GLP-1 RA therapy.GLP-1 RAs show clinically relevant effects in several urological domains: increase in total testosterone and improvement in erectile function in men with obesity-related hypogonadism, nephroprotection with reduction of albuminuria and slowing of eGFR decline, signals of reduced prostate cancer risk in epidemiological studies, and indirect benefit for stress incontinence and overactive bladder via weight loss. At the same time, clinically relevant warning signals exist: a 4.5-fold increased risk of new-onset erectile dysfunction in non-diabetic obese men on semaglutide, novel urological adverse effects in case reports, perioperative aspiration risk through delayed gastric emptying, and a near-complete absence of data in women.GLP-1 RAs represent both a therapeutic opportunity and a clinical challenge for urologists. Systematic andrological and nephrological monitoring as well as proactive patient education on urogenital and perioperative implications is recommended. Prospective controlled trials with urological endpoints are needed.
-
Peri-operative glucagon-like peptide-1 receptor agonist use and outcomes: a national prospective multicentre cohort study.
AI summary of the abstract, unverified
- National prospective multicentre cohort of 47,039 adults across 119 UK sites, undergoing anaesthetist-led procedures and screened for GLP-1 RA use in the prior 3 months.
- GLP-1 RA use was reported by 1348 patients (2.9%), and their peri-operative drug cessation and airway management varied considerably.
- Pulmonary aspiration and/or regurgitation occurred in 1.41% (95% CI 0.85-2.19%) of GLP-1 RA patients versus 0.12% (0.09-0.16%) of others; OR 11.39 (6.47-20.05), p<0.001.
- In the GLP-1 RA group, events most often happened during emergence from anaesthesia, with an overall incidence of about 1 in 71.
Original abstract (PubMed)
INTRODUCTION: Peri-operative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with delayed gastric emptying. It is unclear what proportion of patients having anaesthetic care are receiving GLP-1 RAs; what strategies are used in their peri-operative management; and whether the incidence of pulmonary aspiration and/or regurgitation is greater in this population. METHODS: We performed a national prospective multicentre cohort study of adults undergoing elective or emergency procedures under the care of an anaesthetist. Patients were screened for GLP-1 RA use in the 3 months before the index procedure. Data were collected on patient, procedure, anaesthesia and outcomes, including pulmonary aspiration and regurgitation. The primary outcome was the proportion of patients receiving GLP-1 RAs. Secondary outcomes described the pre-operative management of GLP-1 RAs; anaesthesia and airway management in patients receiving GLP-1 RAs; and the incidence of pulmonary aspiration and/or regurgitation. RESULTS: Of 47,039 patients from 119 sites across the UK, 1348 (2.9%) reported receiving GLP-1 RAs. Peri-operative management was variable regarding drug cessation, anaesthesia and airway management. The incidence (95%CI) of pulmonary aspiration and/or regurgitation in the non-GLP-1 RA cohort was 57/45,691 (0.12% (0.09-0.16%)) and in the GLP-1 RA cohort was 19/1348 (1.41% (0.85-2.19%)); odds ratio (95%CI) 11.39 (6.47-20.05), p < 0.001. In patients receiving GLP-1 RAs, pulmonary aspiration and/or regurgitation occurred most frequently during emergence from anaesthesia. DISCUSSION: In this national study, 1 in 36 patients undergoing anaesthesia care received GLP-1 RAs, and their peri-operative management was variable. A range of airway management techniques aiming to reduce pulmonary aspiration risk were observed but, despite this, the incidence of pulmonary aspiration and/or regurgitation was 1 in 71 in people receiving GLP-1 RAs.
-
Predictors of Perioperative Major Adverse Cardiovascular Events After Bariatric Surgery.
AI summary of the abstract, unverified
- Registry analysis of 1,095,255 adults undergoing primary sleeve gastrectomy or Roux-en-Y gastric bypass in MBSAQIP from 2019 to 2024.
- Thirty-day MACCE occurred in 1,368 patients (0.12%) and was more frequent after gastric bypass than after sleeve gastrectomy.
- Independent predictors included dialysis dependence, prior myocardial infarction, prior pulmonary embolism, male sex, insulin-dependent diabetes, and antihypertensive burden, with heart failure also associated in a subset.
- The authors conclude that risk reflects advanced systemic disease severity more than common comorbidities alone, and they advise prioritizing end-organ disease, insulin dependence, resistant hypertension, and established cardiovascular disease in preoperative evaluation.
Original abstract (PubMed)
Perioperative major adverse cardiac and cerebrovascular events (MACCE) after metabolic and bariatric surgery are uncommon but clinically important, particularly as the profile of patients undergoing surgery evolves in the era of expanded glucagon-like peptide-1 receptor agonist use. We analyzed adults undergoing primary laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass in the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program registry from 2019 to 2024 to determine the contemporary incidence of 30-day MACCE and identify independent predictors of risk. Among 1,095,255 patients, 1,368 experienced a 30-day major adverse cardiac or cerebrovascular event, corresponding to an incidence of 0.12%. Events were more frequent after Roux-en-Y gastric bypass than sleeve gastrectomy. In multivariable analysis, the strongest independent predictors included dialysis dependence, previous myocardial infarction, previous pulmonary embolism, male sex, insulin-dependent diabetes, and greater antihypertensive medication burden. Each additional antihypertensive medication was associated with higher odds of perioperative events, supporting treatment intensity as a marker of cardiometabolic disease severity. In a subset with available heart failure data, heart failure was also independently associated with increased risk. These findings suggest that perioperative cardiovascular risk after metabolic and bariatric surgery is driven less by the presence of common comorbidities alone and more by markers of advanced systemic disease severity. Contemporary preoperative evaluation should prioritize patients with end-organ disease, insulin dependence, resistant hypertension, and established cardiovascular disease to guide optimization and individualized perioperative risk assessment.
-
Preoperative GLP-1 receptor agonist use and outcomes after total hip arthroplasty: a matched cohort study.
AI summary of the abstract, unverified
- Matched cohort study using TriNetX data, with 1262 propensity-matched adults per group undergoing primary THA from 2003 to 2023.
- Patients with at least three GLP-1 receptor agonist prescriptions within one year before surgery were compared with matched controls.
- At 90 days, GLP-1 RA users had lower DVT (1.6% vs 3.0%; RR 0.53, 95% CI 0.31-0.89; p=0.014) and readmission (1.1% vs 2.8%; RR 0.40, 95% CI 0.22-0.71; p=0.001).
- No significant differences were seen in other 90-day outcomes or in 5-year mechanical outcomes, such as PJI and all-cause revision survival.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed among total hip arthroplasty (THA) candidates, yet their perioperative impact remains unclear. METHODS: Using TriNetX, we identified adults undergoing primary THA (2003-2023) with preoperative GLP-1 RA exposure (⩾3 prescriptions within 1 year of surgery) versus controls. 1:1 propensity score matching for demographics, comorbidities, and baseline labs yielded 1262 patients per cohort. Outcomes included 90-day medical complications and mechanical complications (PJI, dislocation, aseptic loosening, periprosthetic fracture, all-cause revision) at 1, 2, and 5 years, reported in accordance with the STROBE guidelines. RESULTS: At 90 days, the GLP-1 RA cohort demonstrated significantly lower risks of DVT (1.6% vs. 3.0%; RR 0.53, 95% CI, 0.31-0.89; p = 0.014) and hospital readmission (1.1% vs. 2.8%; RR 0.40, 95% CI, 0.22-0.71; p = 0.001). No significant differences were found in other 90-day outcomes or in mechanical complications, including all-cause revision (94.6% vs. 95.5% survival; p = 0.674) and PJI (94.7% vs. 94.4%; p = 0.465) at 5 years. CONCLUSIONS: Consistent preoperative GLP-1 RA use is associated with reduced 90-day DVT and readmission following primary THA without increased risk of other complications or mechanical outcomes at 5 years. As DVT was the only significant thromboembolic endpoint, prospective investigation is needed before attributing a thromboprophylactic effect to these agents.
-
Evaluating the safety of glucagon-like peptide-1 agonist use in non-diabetic overweight patients undergoing shoulder arthroplasty.
AI summary of the abstract, unverified
- This database study matched 462 obese, non-diabetic GLP-1 users 1:10 to 4,377 non-users undergoing shoulder arthroplasty, using PearlDiver data from 2010 to 2023.
- GLP-1 users were compared with matched non-users on 90-day and 2-year outcomes after anatomic or reverse total shoulder arthroplasty.
- At 90 days, GLP-1 users had higher readmission (OR 2.034; 95% CI 1.594-2.578; P < .001) and overall complication rates (OR 1.474; 95% CI 1.295-1.799; P < .001).
- No differences were seen at 2 years for prosthetic joint infection, fracture, or all-cause revision, and the authors suggest perioperative GLP-1 use may be reasonable while readmissions warrant intervention.
Original abstract (PubMed)
BACKGROUND: Initially indicated for diabetes mellitus (DM), glucagon-like peptide 1 (GLP-1) agonists are now indicated for obesity management in isolation of DM. While prior studies have examined post-operative outcomes after total shoulder arthroplasty (TSA) in GLP-1 users with DM, there is a paucity of literature evaluating its use in non-diabetic patients for weight loss rather than glucose control. Therefore, our analysis compared 90-day and 2-year outcomes following TSA between non-diabetic obese GLP-1 users and a matched cohort of obese GLP-1 non-users. METHODS: The PearlDiver Mariner database was queried to identify patients who underwent anatomic TSA and reverse TSA between 2010 and 2023. Patients with a history of DM or who underwent TSA for cancer, infection, or pathologic fractures were excluded. Patients with a body mass index ≥ 30 kg/m2 within 6 months of surgery were included. GLP-1 users (within 3 months of surgery) were matched in a 1:10 ratio to GLP-1 non-users by age, sex, Elixhauser Comorbidity Index, smoking status, and various comorbidities. Multivariate logistic regression models were utilized to compare outcomes at 90 days and 2 years. RESULTS: After matching, 462 GLP-1 users and 4,377 GLP-1 non-users were included in our analysis. GLP-1 users had higher readmission rates (odds ratio: 2.034; 95% confidence interval: 1.594-2.578; P < .001) and subsequently overall complication rates (odds ratio: 1.474; 95% confidence interval: 1.295-1.799; P < .001) compared to GLP-1 non-users at 90 days. However, no differences were seen between cohorts for the remaining 90-day outcomes nor for all evaluated 2-year outcomes including prosthetic joint infection, fracture, and all-cause revision. DISCUSSION: Our analysis found a higher incidence of overall complications at 90 days among obese, non-diabetic GLP-1 users, driven largely by an increased incidence of readmissions. However, there were largely comparable outcomes at 2 years. These findings suggest that while GLP-1 agonists may be reasonable to use in the perioperative period, interventions to reduce readmissions among these patients may be warranted.
-
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
AI summary of the abstract, unverified
- Retrospective comparative observational study of 196 patients (98 per group) undergoing high-definition lipoabdominoplasty under general anesthesia.
- Group A received semaglutide or tirzepatide, while Group B received no GLP-1 receptor agonist therapy.
- No statistically significant between-group differences were found in intraoperative adverse events, recovery times, nausea and vomiting, pain scores, or early complications; the abstract gives no effect sizes or p values.
- The authors state these null findings do not show equivalence, since the study was not designed for non-inferiority testing and may be underpowered for rare events.
Original abstract (PubMed)
INTRODUCTION: The increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) for pharmacological weight loss has led to a growing number of patients undergoing body-contouring procedures after rapid weight reduction. Given their effects on gastric emptying, metabolism, and nutritional status, concerns have been raised regarding potential implications for anesthetic management and perioperative safety. However, clinical data addressing anesthetic outcomes in this population remain limited. METHODS: This retrospective comparative observational study included patients undergoing highdefinition lipoabdominoplasty under general anesthesia. Group A consisted of patients receiving GLP-1 receptor agonists (semaglutide or tirzepatide), while Group B included patients not receiving such therapy. All patients underwent standardized preoperative assessment and surgical management. Primary outcomes were intraoperative adverse events, including respiratory complications, hemodynamic instability, and arrhythmias. Secondary outcomes included perioperative parameters (anesthesia and surgical duration, intraoperative EtCO₂ and SpO₂), recovery metrics (time to awakening, mobilization, and discharge), and early postoperative complications. Statistical comparisons were performed using appropriate parametric and non-parametric tests. RESULTS: A total of 196 patients were included (98 per group). No statistically significant Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation differences were observed between groups in demographic or baseline characteristics. Intraoperative parameters remained stable in both groups, with no clinically relevant respiratory events reported. Recovery profiles showed similar trends, with comparable times to awakening, mobilization, and discharge. The incidence of postoperative nausea and vomiting, pain scores, and early complications (seroma, infection, delayed wound healing, and hyperpigmentation) did not differ significantly between groups. DISCUSSION: Within the limitations of this study, no statistically significant differences were observed between patients receiving GLP-1 receptor agonists and controls in terms of intraoperative stability, recovery profile, and early postoperative outcomes. CONCLUSION: These findings should not be interpreted as evidence of equivalence, as the study was not designed for non-inferiority or equivalence testing and may be underpowered for rare events. Further prospective studies with larger sample sizes and stratification by specific GLP-1 receptor agonists are warranted. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
-
Delayed gastric emptying in adolescent patients on glucagon-like peptide-1 receptor agonists with standard preoperative fasting guidelines: a prospective cohort study.
AI summary of the abstract, unverified
- Prospective single-institution cohort of 67 adolescents aged 10-18 yr, divided into a GLP1-RA group (n=20), an at-risk group not on GLP1-RAs (n=27), and healthy controls (n=20).
- All patients followed standard fasting of 8 h for solids and 1 h for clear liquids, and gastric contents were assessed by gastric ultrasound.
- Solids were present in 16/20 (80%) of the GLP1-RA group, versus 17/27 (63%) of the at-risk group and 1/20 (5%) of controls (unadjusted P<0.001; adjusted P<0.02).
- The authors conclude that most adolescents on GLP1-RAs still had solids on ultrasound despite median fasting over 12 h.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are approved in patients aged ≥10 yr for type 2 diabetes mellitus and aged ≥12 yr for obesity. We examined the effect of GLP1-RAs on the retention of gastric contents in fasting adolescents. METHODS: This prospective cohort study examined adolescent patients (10-18 yr) at a single institution between June 2023 and November 2024. Three groups were compared: a GLP1-RA group; a group at-risk for delayed gastric emptying not on GLP1-RAs; and a healthy control group. All patients fasted 8 h for solids and 1 h for clears liquid. Gastric contents were examined utilising gastric ultrasound qualitatively on a 3-point scale, and quantitatively. The primary outcome was the number of adolescents on GLP1-RAs with residual gastric contents (presence of solids or gastric fluid volume ≥1.5 ml kg-1). RESULTS: In total, 67 patients were analysed: 20 in the GLP1-RA group; 27 in the at-risk group; and 20 in the control group. The median age was 14.8 (interquartile range [IQR] 13.2-16.6) yr, and median fasting durations for solids and clears were 13 h (IQR 12-14) and 12 h (IQR 3.5-13), respectively. In the GLP1-RA group, 16/20 patients (80%) had solids present on gastric ultrasound, compared with 17/27 patients (63%) in the at-risk group and 1/20 patient (5%) in the control group (unadjusted P <0.001; adjusted P <0.02, with propensity score adjustment for age, body mass index, sex, race, and NPO time). CONCLUSIONS: We observed that 80% of adolescents on GLP1-RAs had solids on gastric ultrasound despite having fasted for over 12 h.
-
The impact of glucagon-like peptide-1 (GLP-1) receptor agonists on postoperative outcomes following rotator cuff repair.
AI summary of the abstract, unverified
- Retrospective TriNetX cohort of 5,876 adults with type II diabetes undergoing rotator cuff repair from 2018 to 2024, including 233 preoperative GLP-1 agonist users.
- Compared preoperative GLP-1 agonist exposure with non-exposure for 90-day medical, surgical, and healthcare utilization outcomes, using unadjusted and inverse propensity score-weighted logistic regression.
- Unadjusted analyses showed higher odds of respiratory complications (OR 1.97, 95% CI 1.32-2.86), UTI (OR 3.85), and stiffness (OR 2.20); after weighting, no significant differences.
- The authors found no independent association between GLP-1 use and complication risk and suggest perioperative continuation may be safe, while calling for prospective studies.
Original abstract (PubMed)
BACKGROUND: Patients with type II diabetes mellitus (T2DM) undergoing rotator cuff repair (RCR) have increased postoperative risk. Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly used in T2DM, but their perioperative safety remains uncertain. This study evaluated the association between preoperative GLP-1 agonist exposure and postoperative outcomes following RCR. METHODS: A retrospective cohort study using the TriNetX Research Network identified adults with T2DM undergoing RCR between 2018 and 2024. Patients were stratified by preoperative GLP-1 agonist exposure. Outcomes included 90-day medical complications, surgical complications, and healthcare utilization. Univariate and inverse propensity score-weighted binary logistic regression were performed to adjust for confounding. RESULTS: Among 5876 patients, 233 used GLP-1 preoperatively. Unadjusted analyses revealed increased odds of postoperative respiratory complications (odds ratio (OR): 1.97, 95% confidence interval (CI): 1.32-2.86, P = 0.0006), urinary tract infection (OR: 3.85, 95% CI: 1.31-9.12, P = 0.0055), and postoperative stiffness (OR: 2.20, 95% Cl: 1.31-3.49, P = 0.0016) among GLP-1 users. After inverse propensity score-weighting, no significant differences in postoperative outcomes were observed. DISCUSSION: Preoperative GLP-1 agonist use was not independently associated with decreased or increased risk of postoperative complications following RCR. These findings suggest perioperative continuation of GLP-1 therapy may be safe, though prospective studies are warranted.
-
Impact of GLP-1 dose intensity on perioperative and long-term fusion outcomes following ACDF.
AI summary of the abstract, unverified
- Retrospective TriNetX cohort of adults undergoing ACDF; the primary high-dose versus standard-dose comparison included 921 propensity-matched patients per arm.
- Exposure was the GLP-1 receptor agonist prescription strength recorded from 1 year to 1 week before surgery, comparing high-dose with standard-dose use.
- Ninety-day readmission was 11.4% versus 10.0% (p=.327), and opioid exposure was 85.2% versus 83.1% (p=.202), with no significant differences in complications or fusion outcomes.
- Both standard-dose and high-dose users had lower pseudarthrosis rates than nonusers, but higher dose added no further long-term benefit, and the authors conclude high-dose therapy does not add perioperative or fusion risk.
Original abstract (PubMed)
BACKGROUND CONTEXT: High-dose glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for obesity management, but their perioperative safety and potential effects on fusion-related outcomes after anterior cervical discectomy and fusion (ACDF) remain unclear. PURPOSE: To compare short-term postoperative outcomes and longer-term fusion-related outcomes after ACDF among patients receiving high-dose versus standard-dose GLP-1 RA therapy. STUDY DESIGN/SETTING: Retrospective cohort study using the TriNetX Research Network. PATIENT SAMPLE: Adult patients undergoing ACDF were identified within TriNetX and stratified into 3 pairwise comparison groups: standard-dose GLP-1 RA versus no GLP-1 exposure, high-dose GLP-1 RA versus no GLP-1 exposure, and high-dose versus standard-dose GLP-1 RA use. A total of 112,065 patients met inclusion criteria across all 3 comparisons. In the primary dose-intensity comparison, 921 patients remained in each cohort after 1:1 propensity score matching. OUTCOME MEASURES: Outcomes included 90-day healthcare utilization (readmission, emergency department visits, outpatient visits, physical therapy utilization), 90-day medical and acute postoperative complications, 90-day opioid exposure, and long-term fusion-related outcomes from 180 to 720 days, including pseudarthrosis and posterior cervical fusion. METHODS: Data were queried on March 9, 2026. Adults undergoing ACDF were identified and stratified by preoperative GLP-1 RA dose intensity. Exposure was defined by recorded GLP-1 RA prescription strength from 1 year to 1 week before the index ACDF procedure. Separate 1:1 propensity score matching was performed for each pairwise comparison. Outcomes were evaluated at 1-90 days for healthcare utilization, short-term complications, and opioid exposure, and at 180-720 days for long-term fusion-related outcomes. RESULTS: In the primary high-dose versus standard-dose comparison, 90-day healthcare utilization was similar, including readmission (11.4% vs. 10.0%; p=.327), emergency department visits (11.4% vs. 12.3%; p=.564), outpatient visits (49.8% vs. 52.1%; p=.328), and physical therapy utilization (42.0% vs. 44.0%; p=.397). Short-term complications were also similar, including composite medical complications (9.6% vs. 8.9%; p=.629), dysphagia (10.6% vs. 11.2%; p=.709), hematoma (6.8% vs. 6.3%; p=.638), dysphonia (1.8% vs. 1.6%; p=.721), and acute respiratory failure (2.3% vs. 1.7%; p=.406). Opioid exposure did not differ between cohorts (85.2% vs. 83.1%; p=.202). Long-term outcomes were likewise similar, including pseudarthrosis (4.0% vs. 3.8%; p=.822) and posterior cervical fusion (3.0% vs. 3.7%; p=.398). Compared with matched nonusers, both standard-dose and high-dose GLP-1 RA users had lower pseudarthrosis rates, although no additional long-term benefit was observed with higher-dose therapy. CONCLUSIONS: High-dose GLP-1 RA therapy was not associated with increased short-term healthcare utilization, postoperative complications, opioid exposure, or long-term fusion-related risk after ACDF compared with standard-dose therapy. These findings provide reassurance that higher-dose GLP-1 regimens do not appear to confer excess perioperative or fusion-related risk in this population.
-
Glucagon-like Peptide-1 receptor agonist use is associated with decreased risk of periprosthetic joint infection following total knee arthroplasty: A laterality-verified propensity matched comparison.
AI summary of the abstract, unverified
- This retrospective TriNetX database study propensity-matched 1:1 GLP-1 RA users with non-user controls undergoing total knee arthroplasty, tracking outcomes over 2 years.
- The exposure was GLP-1 RA use within the year before TKA, compared with non-users, with laterality assessed to attribute complications to the operated knee.
- PJI was lower in users (1.5% vs. 2.0%; RR 0.74; 95% CI 0.57 to 0.96; P = 0.02), and the difference persisted among diabetic patients (RR 0.68; 95% CI 0.52 to 0.89; P < 0.01).
- Revision, mechanical loosening, periprosthetic fracture, and other mechanical complications did not differ, which the authors interpret as a selective effect against infection.
Original abstract (PubMed)
IntroductionDiabetes and obesity are associated with increased risk of complications following total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a modality for optimizing weight and glycemic control in the perioperative period. This study aims to compare 2-year postoperative complications between GLP-1 RA users and non-users, using laterality-verified methodology to ensure ipsilateral outcome attribution.MethodsA retrospective query of the TriNetX database identified patients who underwent TKA and used GLP-1 RAs within a 1-year preoperative period. GLP-1 RA patients were 1:1 propensity matched to non-user controls for demographics and confounding comorbidities. Laterality was assessed independently to ensure ipsilateral TKA and corresponding complication. Outcomes analyzed were TKA revision, periprosthetic joint infection (PJI), mechanical loosening, periprosthetic fracture, and other mechanical complications within a 2-year postoperative period. Results were further stratified to isolate outcomes among diabetic patients. Results were reported as risk ratios, 95% confidence intervals, and P values.ResultsGLP-1 RA users experienced significantly lower rates of PJI (1.5% vs. 2.0%; RR 0.74; 95% CI 0.57, 0.96; P = 0.02) compared to non-users in a 2-year postoperative period. Among diabetic patients, GLP-1 RA users had significantly lower PJI rates (1.7% vs. 2.5%; RR 0.68; 95% CI 0.52, 0.89; P < 0.01). There were no significant differences between rates of revision, mechanical loosening, periprosthetic fractures, or other mechanical complications in the overall or diabetic-only cohorts.ConclusionGLP-1 RA use was associated with a reduced risk of PJI in a 2-year postoperative period without any significant differences in mechanical outcomes in both overall and diabetic-only cohorts. This laterality-verified analysis provides more accurate outcome attribution than prior database studies and supports a selective protective effect of GLP-1 RAs against infection-related rather than mechanical complications following TKA.
-
Safety and Glycemic Efficacy of Perioperative Liraglutide in Cardiac Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of 4 RCTs (7 reports, 446 randomized adults) comparing perioperative subcutaneous liraglutide with placebo or insulin-based usual care in cardiac surgery.
- Liraglutide was compared with placebo or insulin usual care, with glycemic efficacy and hypoglycemia risk as the central questions.
- Liraglutide did not change 30-day mortality (1/161 vs 3/160; RR 0.42, 95% CI 0.06-2.81) or the composite postoperative complication outcome (RR 0.92, 95% CI 0.74-1.14).
- Hypoglycemia was similar (8/165 vs 9/166; RR 0.85, 95% CI 0.34-2.13), and nausea/vomiting estimates were very imprecise (RR 3.01, 95% CI 0.26-35.27).
Original abstract (PubMed)
Perioperative hyperglycemia in cardiac surgery is associated with wound infection, acute kidney injury, and death, yet the intravenous insulin used to treat it is itself coupled to hypoglycemia. Glucagon-like peptide-1 receptor agonists lower glucose only when glucose is elevated and might therefore separate glycemic control from hypoglycemic risk. We searched PubMed/MEDLINE, Scopus, Web of Science, and CENTRAL through September 2025 for randomized controlled trials of perioperative subcutaneous liraglutide versus placebo or insulin-based usual care in adults undergoing cardiac surgery. Two reviewers screened, extracted data, and applied the Cochrane Risk of Bias 2 tool independently; certainty was graded using GRADE. Effects were pooled by inverse variance, fixed-effect when I2 was below 50%. Seven reports of 4 trials, enrolling 446 randomized patients, were eligible. Liraglutide did not alter 30-day mortality (1/161 vs 3/160; risk ratio [RR] 0.42, 95% confidence interval [CI], 0.06-2.81), the composite of any postoperative complication (68/129 vs 76/132; RR 0.92; 95% CI, 0.74-1.14), cardiac adverse events (RR 1.08; 95% CI, 0.83-1.40), hypoglycemia (8/165 vs 9/166; RR 0.85; 95% CI, 0.34-2.13), or postoperative nausea and vomiting (RR 3.01; 95% CI, 0.26-35.27).
-
What is the association between insulin dependence and the incidence of postoperative complications, perioperative glucose control, and five-year reoperation rates after total joint replacement?
AI summary of the abstract, unverified
- Retrospective single-centre cohort of 830 patients with diabetes undergoing primary THA or TKA from 2015 to 2022, split into insulin-dependent (351) and non-insulin-dependent (479) groups.
- The exposure was insulin dependence, compared with non-insulin-dependent diabetes, and outcomes were 90-day complications, perioperative glucose control, and mid-term reoperation.
- 90-day complications occurred in 35.9% of insulin-dependent patients versus 16.3% of others (p < 0.01), with an adjusted odds ratio of 2.81 (95% CI 1.98 to 3.98).
- Insulin dependence was also associated with poorer perioperative glucose control, while reoperation rates were similar between groups; the authors frame it as a risk marker beyond HbA1c.
Original abstract (PubMed)
AIMS: Diabetes mellitus (DM) is associated with adverse outcomes following total hip arthroplasty (THA) and total knee arthroplasty (TKA), yet optimal perioperative risk stratification remains unclear. This study evaluated the association of insulin dependence with: 1) 90-day complications; 2) perioperative glucose control; and 3) mid-term reoperations in diabetic patients undergoing primary THA and TKA. METHODS: We performed a retrospective, single-centre study of patients with DM undergoing primary THA or TKA between 2015 and 2022. Patients with preoperative glycated haemoglobin (HbA1c) ≥ 6.5 were categorized as insulin-dependent DM (IDDM) or insulin-independent DM (NIDDM). Demographic and clinical variables including preoperative haemoglobin A1C and oral DM medication usage were recorded. The primary outcome was 90-day complications. Secondary outcomes included mean and maximum perioperative glucose levels and reoperations. Multivariable logistic and linear regression analyses were used to evaluate association between insulin dependence and outcomes while adjusting for relevant confounders. RESULTS: A total of 830 patients were included: 351 (42.3%) with IDDM and 479 (57.7%) with NIDDM. Overall, 90-day complications were more common in the IDDM cohort (35.9% vs 16.3%, p < 0.01). Insulin dependence was associated with increased odds of 90-day complications (odds ratio 2.81, 95% CI 1.98 to 3.98). Male sex, metformin use, and glucagon-like peptide-1 receptor agonist use were associated with lower complication risk. Preoperative HbA1c was not independently associated with complications. Insulin dependence and preoperative haemoglobin A1C were associated with worse perioperative glucose control. Reoperation rates were similar between groups. CONCLUSION: Insulin dependence is an independent risk factor for 90-day complications and poorer perioperative glucose control, but not reoperation, following primary THA and TKA. These findings suggest insulin dependence is a clinically meaningful risk marker beyond glycaemic indices. Further investigation into optimization strategies to mitigate this perioperative risk is warranted.
-
GLP-1 receptor agonists in elective spine surgery: a systematic review of fusion outcomes, perioperative safety, and procedure-specific risk.
AI summary of the abstract, unverified
- This systematic review qualitatively synthesized 23 studies, mostly retrospective cohorts and propensity-matched database analyses, in adults undergoing elective spine surgery.
- The exposure was documented preoperative or perioperative GLP-1 receptor agonist use, assessed against fusion, infection, readmission, complications, and length of stay.
- Lumbar fusion studies generally reported favorable or neutral associations, though some TLIF cohorts reported adverse ones, while cervical findings varied by surgical approach.
- No included study reported postoperative pancreatitis, and the authors stress that the findings are associations and that perioperative management should be individualized.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in patients with obesity and type 2 diabetes mellitus undergoing elective spine surgery. Although these agents may improve metabolic risk profiles, their associations with spinal fusion, perioperative complications, and procedure-specific outcomes remain incompletely defined. METHODS: We conducted a systematic review and qualitative synthesis of comparative clinical studies evaluating adults undergoing spine surgery with documented preoperative or perioperative GLP-1 RA exposure. Eligible studies assessed fusion-related outcomes, perioperative medical complications, surgical site infection, readmission, length of stay, healthcare utilization or costs, and musculoskeletal outcomes. The review was conducted in accordance with PRISMA 2020 principles, with eligibility criteria defined using a PICOS framework. RESULTS: Twenty-three studies were included, consisting predominantly of retrospective cohort studies and propensity-matched database analyses. Lumbar fusion studies generally reported favorable or neutral associations between GLP-1 RA exposure and pseudarthrosis, infection, readmission, and healthcare utilization, although some transforaminal lumbar interbody fusion cohorts reported adverse associations. Cervical fusion outcomes were more heterogeneous and appeared to vary by surgical approach. Anterior cervical fusion studies generally reported neutral or favorable outcomes, whereas posterior cervical fusion studies yielded conflicting findings. Gastrointestinal safety data were sparse, no included study reported postoperative pancreatitis, and preoperative treatment duration and longitudinal BMI or weight change were incompletely characterized. CONCLUSIONS: Current evidence suggests that GLP-1 RA exposure is associated with procedure-specific differences in outcomes after elective spine surgery. Because the available evidence is predominantly observational, these findings should be interpreted as associations rather than evidence of direct causal benefit or harm. Perioperative GLP-1 RA management should be individualized according to surgical procedure, metabolic status, gastrointestinal symptoms, renal and hydration risk, and nutritional or sarcopenia-related vulnerability.
-
The Effect of Glucagon-like Peptide-1 Receptor Agonists in Total Joint Arthroplasty: Implications, Complications, and Considerations.
AI summary of the abstract, unverified
- This is a narrative review appraising current evidence on perioperative GLP-1 receptor agonist use in total joint arthroplasty patients.
- It covers GLP-1 RA physiology, pharmacology, mechanisms, and commonly used agents, which are used for glycemic control and increasingly for weight loss.
- The review addresses complications, adverse effects, and separate considerations for anesthesiologists and TJA surgeons.
- It also summarizes clinical practice recommendations as of 2025, but the abstract reports no pooled numerical results.
Original abstract (PubMed)
Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1 RAs) are used in diabetic patients for glycemic control. Yet, there has been a notable rise in their use for weight loss management in obese patients. This review critically appraises current evidence on perioperative implications of GLP-1 receptor agonists in TJA patients. The review discusses GLP-1 RA implications and use (physiology, pharmacology, pharmacodynamics, mechanisms of actions, and commonly used GLP-1 Ras), complications and adverse effects, considerations for the anesthesiologist, considerations for the TJA surgeon, and current clinical practice recommendations in 2025.
-
Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair: An Analysis of 1,092 Patients.
AI summary of the abstract, unverified
- Retrospective TriNetX database analysis of 1,092 patients undergoing quadriceps or patellar tendon repair, propensity-matched into two cohorts of 546.
- Exposure was preoperative GLP-1 receptor agonist use within one year of surgery, compared with patients without that use, followed to 90 days, 1 year, and 2 years.
- At 1 year, surgical site infection was lower with GLP-1 use (2.38% vs 5.31%; OR 0.435; P=.0118), as were wound complications (2.02% vs 5.31%; OR 0.367; P=.0037).
- No 90-day or revision surgery differences were found, and the authors suggest possible perioperative risk modulation as GLP-1 use grows.
Original abstract (PubMed)
BACKGROUND: Diabetes and obesity are recognized as risk factors for postoperative complications including increased surgical site infection (SSI) and reoperation in patients undergoing knee extensor mechanism repair. However, limited literature evaluates how preoperative glucagon-like peptide-1 (GLP-1) receptor agonist therapy may influence these outcomes. This study evaluated GLP-1 receptor agonist use as an independent risk factor for postoperative outcomes following knee extensor mechanism repair. MATERIALS AND METHODS: Patients who underwent quadriceps or patellar tendon repair from 2012 to 2025 were identified in the TriNetX database and stratified by GLP-1 agonist use within 1 year of surgery. One-to-one propensity score matching yielded 2 well-balanced cohorts (n = 546). Postoperative complications were assessed at 90 days, 1 year, and 2 years, and Kaplan-Meier survival analysis was performed. RESULTS: No significant 90-day postoperative differences were observed. At 1 year, patients using GLP-1 agonists demonstrated significantly lower rates of SSI (2.38% vs 5.31%; odds ratio [OR] = 0.435; P = .0118) and wound complications (2.02% vs 5.31%; OR = 0.367; P = .0037). Differences persisted at 2 years, with lower rates of SSI (2.75% vs 6.04%; OR = 0.439; P = .0079), wound complications (2.38% vs 6.04%; OR = 0.379; P = .0026), and acute kidney injury (9.71% vs 13.55%; OR = 0.686; P = .0474). No significant differences in revision surgery were found. Kaplan-Meier analysis demonstrated significant separation for SSI and wound complications beginning at 1 year. CONCLUSION: Preoperative GLP-1 receptor agonist therapy was associated with reduced postoperative SSI and wound complications following knee extensor mechanism repair. These findings suggest potential for perioperative risk modulation as GLP-1 use becomes increasingly prevalent in patients undergoing knee extensor mechanism repair.
-
Preoperative Weight Loss Before Total Joint Arthroplasty Using Novel Glucagon-Like Peptide-1 Agonists.
AI summary of the abstract, unverified
- This Level III study identified 6,482 patients who had primary hip or knee arthroplasty between 2019 and February 2023.
- The exposure was preoperative GLP-1 use, which rose from 2% of patients in 2019 to 5% in 2022.
- Among GLP-1 users, mean preoperative weight change was -9 pounds, and 19% lost at least 20 pounds; multivariable models showed no link to complications (P = .85).
- GLP-1 use was not associated with revisions, reoperations, or complications, and the 90-day emergency visit odds ratio was 1.5 (P = .07).
Original abstract (PubMed)
BACKGROUND: This study determined the prevalence of glucagon-like peptide-1 (GLP-1) use before total joint arthroplasty (TJA), measured weight loss of patients on GLP-1s, and evaluated if GLP-1s were associated with outcomes. METHODS: We identified 6482 patients (2990 hips; 3492 knees) who had primary TJAs between 2019 and February 2023. The mean age was 67 years, 50% were female, and 12% had a body mass index ≥40 kg/m2. Univariable and multivariable models evaluated outcomes. Mean follow-up was 3 years. RESULTS: The prevalence of GLP-1s before TJA was 3%, increasing from 2% in 2019 to 5% in 2022. The mean preoperative weight change on GLP-1s was -9 pounds (range, -110 to +36 pounds). Among patients taking GLP-1s, 19% lost ≥20 pounds prior to surgery, and the mean body mass index change was -1.4 kg/m2 (range, -16.3 to 6.2 kg/m2). In univariable analyses, GLP-1 use was not associated with revisions (P = .35), reoperations (P = .09), or complications (P = .23). In multivariable analyses, GLP-1s were not associated with revisions (P = .66), reoperations (P = .34), or complications (P = .85). There was no difference in the risk of a 90-day postoperative emergency department visit between those on GLP-1s vs not on those medications (odds ratio, 1.5; P = .07). CONCLUSIONS: The prevalence of preoperative GLP-1s before TJA increased from 2% in 2019 to 5% in 2022, and preoperative weight change on GLP-1s varied considerably. GLP-1s were not associated with decreased postoperative risks but investigational GLP-1s before TJA require further study. LEVEL OF EVIDENCE: Level III.
-
GLP-1 agonist use and lower rates of pseudarthrosis and dysphagia following anterior cervical discectomy and fusion surgery, with time-dependent effects.
AI summary of the abstract, unverified
- Database analysis of 2345 patients with GLP-1 RA exposure undergoing ACDF (CPT 22551) in TriNetX, 2014–2024, with 1:1 propensity-matched controls.
- Exposure timing was grouped as preoperative, perioperative, or postoperative, with a landmark approach for postoperative initiators to limit immortal time bias.
- Overall use was linked to less pseudarthrosis and dysphagia but not revision; the abstract reports no odds ratios, confidence intervals, or p values.
- Continuous perioperative use was associated with more dysphagia and revision but less sepsis, while postoperative initiation was linked to less pseudarthrosis, especially in patients with diabetes.
Original abstract (PubMed)
OBJECTIVE: Anterior cervical discectomy and fusion (ACDF) is among the most frequently performed spinal procedures in the US. Despite high success rates, complications such as pseudarthrosis, dysphagia, and revision surgery remain clinically significant, particularly in patients with diabetes mellitus (DM) and obesity. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have demonstrated anti-inflammatory and bone-modulating properties in existing clinical and laboratory orthopedic research, yet their relationship to cervical fusion outcomes remains unclear, especially regarding therapy timing. The aim of this study was to evaluate the association between GLP-1 RA use and pseudarthrosis, dysphagia, and revision surgery, as well as perioperative complications, following ACDF surgery. METHODS: TriNetX, a global health research network, was queried (2014-2024) for patients undergoing ACDF surgery (CPT code 22551) with GLP-1 RA exposure. Subcohort analyses were conducted based on overall therapy timing (preoperative, perioperative, and postoperative) and further stratified by initiation and discontinuation timing. Postoperative initiators were analyzed using a landmark approach to mitigate immortal time bias. Each subcohort was 1:1 propensity score-matched to controls by age, sex, race, smoking, DM, BMI, and uremia. Ninety-day outcomes included deep vein thrombosis, pulmonary embolism, emergency department visit, inpatient hospitalization, sepsis, surgical site infection, and wound disruption. Two-year outcomes included pseudarthrosis, dysphagia, and revision surgery. Odds ratios with 95% confidence intervals were calculated using chi-square analysis. RESULTS: Among 2345 patients with GLP-1 RA exposure within 2 years after undergoing ACDF, overall use was associated with reduced pseudarthrosis and dysphagia, but not revision surgery. Preoperative GLP-1 RA use was associated with increased odds of dysphagia when discontinued > 12 months before surgery. Continuous perioperative use was associated with increased odds of dysphagia and revision surgery, as well as reduced odds of sepsis. Postoperative initiation was associated with reduced odds of pseudarthrosis and dysphagia in the overall subcohort, reduced odds of pseudarthrosis in patients with DM, and increased odds of dysphagia in those with multilevel fusion surgeries. CONCLUSIONS: GLP-1 RA use demonstrated timing-dependent associations with outcomes following ACDF surgery. Postoperative initiation of therapy was associated with reduced pseudarthrosis, particularly in patients with DM, and dysphagia, while continuous perioperative exposure increased the risk of dysphagia and revision. These findings suggest a potential role for temporally targeted GLP-1 RA therapy during postoperative healing. Prospective studies are required for validation and to determine causal relationships.
-
Medication Safety and Perioperative Risk Management of GLP-1 Receptor Agonists: A Pharmacist-Led Framework for Individualized Care.
AI summary of the abstract, unverified
- This narrative review summarizes evidence on GLP-1 receptor agonist delayed gastric emptying and proposes a pharmacist-led perioperative risk framework.
- GLP-1 receptor agonists may leave residual gastric contents despite standard fasting, yet outcome studies have not consistently shown more aspiration pneumonia.
- These aspiration findings are limited by rare events, mostly retrospective designs, residual confounding, and inconsistent definitions of residual gastric contents.
- The proposed pathway covers medication verification, symptom screening, risk phenotyping, selective gastric ultrasound, and restart planning, and the authors call for prospective testing.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes, obesity, and broader cardiometabolic, cardiorenal, and metabolic liver disease indications, creating new challenges for perioperative medication safety. This review summarizes current evidence on GLP-1RA-associated delayed gastric emptying and proposes a structured pharmacist-led framework for individualized perioperative risk management. GLP-1RAs may increase the likelihood of residual gastric contents during anesthesia or procedural sedation despite adherence to standard fasting recommendations. Perioperative outcome studies have not consistently shown an increased risk of aspiration pneumonia; however, these findings should be interpreted in light of the low incidence of aspiration-related events, the predominance of retrospective study designs, residual confounding, and heterogeneous definitions of residual gastric contents. We review mechanisms of delayed gastric emptying, treatment- and patient-related risk modifiers, perioperative clinical evidence, areas of agreement and divergence among major guidance statements, gastric ultrasonography as a selective risk-mitigation tool, and medication-safety issues beyond aspiration, including oral drug absorption and postoperative resumption. Because perioperative GLP-1RA decisions require accurate medication history, last-dose verification, symptom assessment, evaluation of glycemic consequences of drug interruption, coordination with anesthesia and surgical teams, and safe postoperative restart planning, pharmacists are well positioned to support this process. The proposed pharmacist-led pathway provides a structured approach to GLP-1RA medication verification, gastrointestinal symptom screening, risk phenotyping, multidisciplinary escalation, day-of-surgery reassessment, postoperative restart planning, patient education, and documentation. Perioperative GLP-1RA management should not rely on routine discontinuation alone, but should integrate treatment phase, dose escalation, gastrointestinal symptoms, comorbid motility disorders, procedural urgency, anesthetic risk, oral medication considerations, and the metabolic consequences of withholding therapy. This pathway represents a structured implementation framework informed by current evidence and guidance; prospective evaluation in real-world perioperative settings is needed.
-
Obesity and Upper Aerodigestive Dysfunction: Voice, Swallowing, Reflux, and Airway Considerations in Laryngology.
AI summary of the abstract, unverified
- This is a narrative review article in Otolaryngologic Clinics of North America, with no original study population or sample size reported.
- It describes how obesity may alter respiratory mechanics, upper airway stability, reflux, esophageal clearance, gastric emptying, and systemic inflammation.
- It covers voice, swallowing, reflux, airway mechanics, and perioperative and postoperative risks, aimed at laryngologists and general otolaryngologists.
Original abstract (PubMed)
Obesity alters upper aerodigestive physiology through changes in respiratory mechanics, upper airway stability, reflux burden, esophageal clearance, gastric emptying, and systemic inflammation. These changes may contribute to a myriad of voice, swallowing, and airway pathologies. This article examines the relationship between obesity and upper aerodigestive tract disorders, focusing on voice, swallowing, reflux, airway mechanics, perioperative/postoperative risks, and management relevant to laryngologists and comprehensive otolaryngologists alike.
-
Prehospital glucagon-like peptide-1 receptor agonists are not associated with reduced inpatient opioid exposure but with shorter hospital length of stay after total joint arthroplasty.
AI summary of the abstract, unverified
- Retrospective cohort of 14,375 hip or knee arthroplasties, with 786 chronic GLP-1RA users propensity-matched 1:1 to 786 non-users.
- The exposure compared was chronic preoperative GLP-1RA therapy versus no GLP-1RA use.
- GLP-1RA use was not associated with lower inpatient opioid administration (adjusted difference -0.18; 95% CI -0.74 to 0.38; p=0.53) or with postoperative MME.
- GLP-1RA users had shorter length of stay (adjusted difference -10.41 hours; 95% CI -13.97 to -6.85; p<0.001), which the authors say needs prospective confirmation.
Original abstract (PubMed)
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been hypothesized to confer anti-inflammatory, antinociceptive, and anti-addictive benefits. We aimed to investigate their impact on acute perioperative pain and opioid use after total joint arthroplasty (TJA). METHODS: A retrospective cohort study analyzed 14,375 hip or knee arthroplasties performed between January 2018 and February 2026, which included 882 patients on chronic preoperative GLP-1RA therapy. Using 1:1 propensity-score matching without replacement, 786 GLP-1RA users were matched to 786 non-users (total n=1,572) based on demographics, surgery type, and chronic medication use. RESULTS: In the matched cohort, chronic GLP-1RA use was not associated with reduced inpatient opioid administration (adjusted difference -0.18; 95% CI, -0.74 to 0.38; p=0.53) or corrected postoperative morphine milligram equivalents (MME) (-2.79 MME; 95% CI, -6.95 to 1.37; p=0.19). When normalized to hospitalization time, the difference in inpatient opioid exposure was not statistically significant (+0.073 MME/hour; 95% CI, -0.003 to 0.149; p=0.059). Average visual analog scale (VAS) pain scores also showed no significant difference (-0.094; p=0.15). However, GLP-1RA users demonstrated a consistently shorter length of stay (LOS) (adjusted difference -10.41 hours; 95% CI, -13.97 to -6.85; p<0.001). CONCLUSIONS: Chronic preoperative GLP-1RA therapy was not associated with reduced inpatient opioid exposure or improved early postoperative pain control following TJA. Nevertheless, GLP-1RA use was consistently associated with shorter hospital LOS. Prospective studies are needed to determine whether this finding reflects improved recovery pathways or residual confounding and to evaluate the impact of GLP-1RAs on longer-term postoperative outcomes and opioid utilization.
-
A noninvasive 13C-mannitol breath test to monitor semaglutide treatment-induced delayed oral-cecal transit in mice.
AI summary of the abstract, unverified
- In this mouse study, the authors developed a noninvasive breath test of oral-cecal transit time using unanesthetized, freely moving animals.
- Orally given 13C-mannitol is metabolized by cecal microbiota to exhaled 13CO2, measured by indirect calorimetry with real-time 13C/12C ratio analysis.
- Pharmacological validation showed sensitivity to delayed transit, including a pronounced semaglutide-induced delay in obese mice; the abstract gives no effect sizes.
- The authors describe the method as high-throughput and longitudinal, improving rigor and reproducibility, and useful for GI physiology and drug studies.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are highly effective treatments for obesity and type 2 diabetes but are often associated with gastrointestinal side effects including delayed transit times through the gastrointestinal tract. We present a noninvasive breath test to measure oral-cecal transit time (OCTT) in mice that could be readily translated to clinical studies. Current methods for measuring OCTT are limited by invasiveness, terminal procedures, anesthesia, radioactive tracers, or stress-induced influence on the outcomes. Here we demonstrate that 13C-labeled mannitol is metabolized by murine cecal microbiota, producing measurable 13CO2 in exhaled breath. Using indirect calorimetry combined with real-time measurement of the 13C/12C ratio, this approach provides a highly granular, noninvasive method to measure OCTT in mice. This technique is performed in unrestrained freely moving animals while enabling high-throughput measurements performed longitudinally. The method improves experimental rigor and reproducibility and provides a valuable tool for studying gastrointestinal physiology and the effects of pharmacologic therapies.NEW & NOTEWORTHY A novel noninvasive assay uses orally administered 13C-mannitol, metabolized by cecal microbiota into exhaled 13CO2, to enable continuous, longitudinal measurement of oral-cecal transit time in unanesthetized, freely moving mice via indirect calorimetry with isotope ratio analysis. Pharmacological validation confirmed sensitivity to delayed transit, including a pronounced semaglutide-induced delay in obese mice that models a clinically relevant glucagon-like peptide-1 (GLP-1) receptor agonist adverse effect.
-
Semaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.
AI summary of the abstract, unverified
- This preclinical study used an LPS-induced inflammatory cognitive impairment model in mice, created by intracerebroventricular injection; the abstract does not report sample size.
- Mice received semaglutide alone or combined with the O-GlcNAc transferase inhibitor OSMI-1 and AKT-silencing adeno-associated viruses.
- Semaglutide reversed LPS-induced cognitive deficits and restored hippocampal O-GlcNAcylation, though the abstract reports no effect sizes or statistics.
- The authors conclude that semaglutide ameliorates perioperative neurocognitive disorder through AKT O-GlcNAcylation, AKT-mTOR activation, and downstream neuroprotection.
Original abstract (PubMed)
Perioperative neurocognitive disorder (PND) manifests as neurocognitive alterations induced by anesthesia and surgical stress. High-risk factors, including advanced age, obesity, diabetes, and preoperative neurological dysfunction, accelerate PND progression, with neuroinflammation serving as a core pathological mechanism throughout PND pathogenesis. Semaglutide regulates neuroinflammation in patients with diabetes and stroke, yet its role in PND remains undefined.A lipopolysaccharide (LPS)-induced inflammatory neurocognitive impairment mouse model was established via intracerebroventricular injection. Mice were treated with semaglutide alone or combined with the O-GlcNAc transferase inhibitor OSMI-1 and AKT-silencing adeno-associated viruses. Behavioral, biochemical and immunofluorescence assays were performed to evaluate cognitive function and molecular changes. Semaglutide significantly rescued LPS-induced cognitive deficits and restored hippocampal O-GlcNAcylation. Mechanistically, LPS inhibited AKT O-GlcNAc modification and AKT-mTOR pathway activity, facilitated mTOR-gephyrin binding, disrupted GABAAR distribution, aggravated neuronal apoptosis, and impaired synaptic plasticity. Semaglutide reversed these abnormalities by elevating AKT O-GlcNAcylation to activate the AKT-mTOR pathway, which triggered mTOR-gephyrin dissociation, restored synaptic GABAAR localization, attenuated neuronal damage, and rescued synaptic plasticity.Semaglutide ameliorates PND via AKT O-GlcNAcylation-mediated AKT-mTOR activation and subsequent neuroprotective effects.
-
Investigating the impact of Glucagon-like peptide-1 therapy on total shoulder arthroplasty outcomes.
AI summary of the abstract, unverified
- This retrospective PearlDiver database study included 95,566 primary total shoulder arthroplasty patients, of whom 1,549 (1.62%) were GLP-1 receptor agonist users.
- GLP-1 users were compared with non-users after 10:1 exact matching on age, sex, Elixhauser index, diabetes, hypertension and overall obesity, with multivariable adjustment for remaining imbalances.
- After adjustment, no significant differences in medical or orthopaedic complications were found, while GLP-1 users had lower 90-day ED visit (OR 0.75; P < .01) and readmission (OR 0.71; P < .01) odds.
- The authors concluded GLP-1 use was not associated with worse outcomes and may be linked to lower healthcare utilisation, though obesity-class subgroup differences were not significant, likely due to small size.
Original abstract (PubMed)
PURPOSE: The increasing prevalence of Glucagon-like peptide-1 receptor agonists (GLP-1 RA) has raised concerns about their perioperative impact. Although database studies on GLP-1 RAs in total shoulder arthroplasty (TSA) have been published for diabetic and general TSA patients, results are conflicting, and the effects on patients across various obesity classes remain unexplored. This study aims to fill this gap. METHODS: The PearlDiver database was used to identify patients who underwent primary TSA, grouped by GLP-1 use, obesity status, and obesity class. Post-operative outcomes included 90-day readmission and emergency department (ED) visit rates, medical complications (including thromboembolic, infectious, and renal events), and orthopaedic complications (including revision, periprosthetic joint infection, and instability). Cohorts were matched 10:1 by exact matching on age, sex, Elixhauser comorbidity index, diabetes, hypertension and overall obesity status, and multivariable regression was used to adjust for comorbidities that remained imbalanced after matching. RESULTS: Among 95,566 patients, 1,549 (1.62%) were GLP-1 users. Initially, GLP-1 users exhibited higher pre-operative comorbidity burdens and rates of complications. However, after matching and multivariable adjustment for residual imbalance, no significant differences in medical or orthopaedic outcomes persisted. Notably, GLP-1 users demonstrated significantly lower odds of 90-day ED visits (OR 0.75; P < .01) and readmissions (OR 0.71; P < .01). Similar trends were observed within each individual obesity class, but none reached statistical significance, most likely reflecting the small size of these subgroups. CONCLUSION: After accounting for pre-operative comorbidities, our findings suggest that GLP-1 RA use is not associated with worse surgical outcomes in TSA patients and may be associated with lower post-operative healthcare utilisation, although residual confounding cannot be excluded. Further longitudinal studies are warranted to optimise perioperative GLP-1 RA administration.
-
Glucagon-like peptide-1 receptor agonists and retained gastric contents on endoscopy: a prospective observational study.
AI summary of the abstract, unverified
- Prospective observational study of 256 patients undergoing elective upper endoscopy, comparing those taking GLP-1 receptor agonists with those not taking them.
- GLP-1 RA users were told to hold the drug for one week and follow a 24-hour clear liquid diet, while controls followed standard 8-hour fasting.
- Retained gastric contents occurred in 8% of GLP-1 RA users versus 6% of controls, a difference that was not statistically significant (P = 0.55), and no aspiration events occurred.
- Endoscopists more often reported concern about significant gastric contents in the GLP-1 RA group (19% vs 7%), and the authors call the study small.
Original abstract (PubMed)
PURPOSE: Retrospective evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with retained gastric contents (RGC) after standard 8-hr fasting, possibly increasing aspiration risk. The primary aim of this study was to compare the incidence of RGC on upper endoscopy after appropriate preoperative fasting in patients taking GLP-1 RAs vs patients not taking GLP-1 RAs. METHODS: We conducted prospective observational study of 256 patients scheduled for elective endoscopy involving stomach visualization. The primary outcome was RGC, defined as solid content or liquid-only content > 1.5 mL·kg-1 body weight. Control patients followed standard 8-hr fasting, while patients taking GLP-1 RAs were instructed to hold this medication 1 week prior and were limited to a preprocedural 24-hr clear liquid diet. We measured RGCvia suctioning whenever possible and recorded subjective physician impressions. Secondary outcomes included aspiration events, procedure abortion, and conversion to general anesthesia. We evaluated the differences between groups using two-sample t tests or Wilcoxon rank-sum test for continuous and ordinal variables and Chi square tests or Fisher's exact test for categorical variables. We analyzed potentially confounding variables via logistic regression. RESULTS: There was no statistically significant difference in the incidence of RGC between patients taking GLP-1 RAs (8%) vs controls (6%, P = 0.55). There were no occurrences of aspiration events, procedure abortion, or relevant conversion to general anesthesia. Endoscopy physician-reported concern of significant gastric contents was higher in the GLP-1 RA group compared with the control group (19% vs 7%). CONCLUSIONS: In this small observational study, no statistically significant increase in RGC was noted when preprocedural instructions advised patients to hold GLP-1 RAs 1 week prior to endoscopy and follow a preprocedural 24-hr clear liquid diet.
-
Preoperative fasting status and retained gastric contents in patients undergoing endoscopy who are using glucagon-like peptide type 1 receptor agonists: a multicentre retrospective study.
AI summary of the abstract, unverified
- Multicentre retrospective cohort of 337 patients on GLP-1 receptor agonists who had elective EGD at five Henry Ford Health System hospitals, 2018 to 2023.
- Preoperative solid-food fasting duration was dichotomized at the median of 15 hours and compared against retained gastric contents as reported in the endoscopy report.
- Retained gastric contents occurred in 8.4% of patients; fasting solids more than 15 hours was associated with lower odds (adjusted OR 0.33; 95% CI 0.13 to 0.81; P = 0.02).
- Liquid fasting, diabetes, GLP-1 RA duration, and suspension within 7 days were not significantly associated with retained contents, and the authors conclude that prolonged solid fasting was linked to lower odds.
Original abstract (PubMed)
PURPOSE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for the management of type 2 diabetes mellitus and obesity. Nevertheless, their known effect of delaying gastric emptying raises perioperative concerns, particularly regarding the risk of pulmonary aspiration. There is limited evidence to guide fasting practices in this population. Our aim was to evaluate the association between preoperative fasting duration and the presence of retained gastric contents (RGC) in patients receiving GLP-1 RAs who underwent esophagogastroduodenoscopy (EGD). METHODS: We conducted a multicentre retrospective cohort study involving 337 patients from five Henry Ford Health System hospitals who underwent elective EGD between January 2018 and December 2023. Eligible patients were actively taking or had recently discontinued a GLP-1 RA within 90 days prior to the procedure. The primary outcome was the presence of RGC, defined as any small, moderate, or large amount of food or gastric material explicitly reported by the endoscopist in the EGD report. For regression analyses, fasting duration for solids was dichotomized at the cohort's median value (15 hr). We performed multivariable logistic regression to evaluate the association between preoperative fasting duration, the timing of GLP-1 RA suspension, and the presence of RGC, adjusting for clinically relevant covariates. RESULTS: The overall prevalence of RGC was 8.4%. In the adjusted model, fasting from solid foods for more than 15 hr was significantly associated with lower odds of RGC (adjusted odds ratio [OR], 0.33; 95% confidence interval [CI], 0.13 to 0.81; P = 0.02). Fasting duration for liquids and presence of diabetes were not significantly associated with RGC. Suspension of GLP-1 RA within less than 7 days of the procedure related to RGC was not statistically significant (adjusted OR, 5.23; 95% CI, 0.67 to 39.38; P = 0.12). No significant association was observed between the duration of GLP-1 RA use and RGC prevalence. CONCLUSIONS: Patients with an active prescription for GLP-1 RA had lower odds of RGC during EGD after more than 15 hr fasting of solids.
-
An Updated Review of Glucagon-Like Peptide-1 Receptor Agonists: Perioperative Implications, Guidance Statements, and Current Literature.
AI summary of the abstract, unverified
- This is a narrative review of glucagon-like peptide-1 receptor (GLP-1) agonists in patients undergoing surgery.
- It covers the history and mechanism of action of these drugs, then recent evidence and perioperative management strategies.
- The abstract highlights delayed gastric emptying and the resulting aspiration risk during anesthesia as the central concern, but reports no specific findings or numbers.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor (GLP-1) agonist medications are becoming a commonly prescribed medication for patients undergoing surgical procedures. Perioperative management of this medication has become an important topic due to the known delayed gastric emptying leading to the potential for retained gastric contents elevating the risk for aspiration during anesthesia. This update will briefly review the history and mechanism of action of these medications. We will then pivot to discuss recent evidence and best practice strategies in managing perioperative patients on GLP-1 therapy.
-
Beyond Weight Loss: A Comprehensive Review of Integrated Pharmacotherapy and Metabolic Bariatric Surgery in Endometrial Cancer Care.
AI summary of the abstract, unverified
- This is a narrative review following SANRA criteria, synthesizing evidence on metabolic interventions in women with severe obesity and endometrial cancer, with no pooled patient numbers reported.
- The interventions reviewed are minimally invasive metabolic/bariatric surgery, including combined surgery with hysterectomy, and GLP-1 receptor agonists.
- The review finds combined bariatric surgery and hysterectomy appears feasible for selected patients, and GLP-1RAs may affect obesity-related and tumor-associated pathways, but direct antitumor benefit is not established.
- The authors conclude obesity is modifiable, weight reduction lowers endometrial cancer risk, but cancer-specific survival benefit is undemonstrated and prospective studies are needed before guideline inclusion.
Original abstract (PubMed)
Backgroundand Objectives: Endometrial cancer ranks among the most prevalent gynecologic malignancies in high-income countries, with increasing incidence and mortality driven by the global obesity epidemic. Evidence suggests that women with early-stage disease face a greater risk of death from obesity-related comorbidities than from cancer recurrence and that weight reduction is associated with improvements in quality of life and in the long-term burden of obesity-related morbidity and mortality. Minimally invasive (MIS) metabolic/bariatric surgery is the most effective treatment for achieving significant, sustained weight loss and comorbidities resolution/improvement. Advances in MIS (laparoscopic, robotic, and endoscopic) techniques have reduced perioperative morbidity and mortality. Novel pharmacotherapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), have recently received regulatory approval for weight management and ongoing studies are investigating their therapeutic impact on endometrial carcinogenesis and tumor biology. This review synthesizes and critically appraises evidence on metabolic interventions, including innovative bariatric techniques and pharmacologic agents, with the aim of informing their integration into multidisciplinary, risk-adapted management strategies for patients with severe obesity and endometrial cancer. Materials and Methods: A comprehensive review was conducted in accordance with SANRA (Scale for the Assessment of Narrative Review Articles) criteria. Results: Emerging evidence indicates that MIS metabolic/bariatric surgery combined with hysterectomy is feasible and may be integrated into the multidisciplinary management of selected patients with severe obesity and endometrial hyperplasia or carcinoma. GLP-1RAs may modulate both the obesogenic systemic milieu and selected tumor-associated pathways, although definitive clinical evidence of direct antitumor effect and oncologic benefit in endometrial cancer has not been established. Conclusions: Obesity is a modifiable risk factor for endometrial cancer. Metabolic/bariatric interventions represent a promising component of the comprehensive, patient-centered management of this disease. Prospective studies are essential to clarify the association between these interventions and longitudinal oncologic outcomes, the feasibility and potential benefits of combined approaches, and their differential impact according to the molecular classification of endometrial cancers. Although weight reduction is associated with a lower risk of endometrial cancer, a direct improvement in cancer-specific survival has not yet been demonstrated; weight-loss management therefore represents a promising component of care in the severely obese population, and its incorporation into formal guidelines requires confirmation in prospective studies.
-
Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes.
AI summary of the abstract, unverified
- This systematic review pooled 12 case reports describing 13 adults who developed gastroparesis while taking a GLP-1 receptor agonist.
- Semaglutide was the agent most often implicated, followed by liraglutide, dulaglutide, and exenatide, with symptoms often following dose escalation or inappropriate re-initiation.
- Stopping the causative GLP-1 receptor agonist resolved symptoms in all reported patients, though the review reports no effect sizes or confidence intervals.
- The authors call for awareness of this association and recommend careful patient selection, gradual dose titration, and monitoring for persistent GI symptoms.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the treatment of type 2 diabetes mellitus and obesity. Although gastrointestinal adverse effects are common, gastroparesis is an under-recognised but clinically important complication. This systematic review summarises published evidence on the presentation, diagnosis, management, and outcomes of gastroparesis associated with GLP-1RA therapy in real-world clinical practice. METHODS: A systematic review was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception to October 2025 for reports of symptomatic gastroparesis associated with GLP-1RA use. Eligible studies included case reports, case series, observational studies, and clinical trials involving adults treated with GLP-1RAs for diabetes or weight loss. Data extraction focused on patient characteristics, GLP-1RA exposure, clinical presentation, diagnostic findings, management strategies, and outcomes. Methodological quality was assessed using the Joanna Briggs Institute checklist for case reports. RESULTS: Twelve case reports describing 13 patients met inclusion criteria. Most patients were female and had type 2 diabetes mellitus, though cases also occurred in non-diabetic individuals. Semaglutide was the most frequently implicated agent, followed by liraglutide, dulaglutide, and exenatide. Symptom onset ranged from hours to several months after treatment initiation, commonly following dose escalation or inappropriate re-initiation. Presentations varied from acute to chronic. Reported symptoms included nausea, vomiting, abdominal pain, bloating, early satiety, and oral intolerance. Diagnostic evaluation often demonstrated gastric distension or retained gastric contents on imaging or endoscopy in the absence of mechanical obstruction. Gastric emptying scintigraphy confirms delayed emptying in selected cases. Management primarily involved supportive and symptomatic care. Discontinuation of the offending GLP-1RA led to symptom resolution in all reported patients. CONCLUSION: GLP-1 receptor agonists may induce or worsen gastroparesis in both diabetic and non-diabetic patients, particularly following rapid dose escalation or inappropriate dosing. Awareness of this association is essential for timely diagnosis and management. Withdrawal of the causative agent is central to treatment and is associated with favourable outcomes and reversibility of gastric dysfunction. Careful patient selection, gradual dose titration, and monitoring for persistent gastrointestinal symptoms are recommended to optimise the safe use of GLP-1RAs.
-
Perioperative Optimization Strategies in Major Genitourinary Cancer Surgery.
AI summary of the abstract, unverified
- This narrative literature review drew on PubMed-indexed trials, observational studies, systematic reviews, and guidelines on perioperative optimization for genitourinary cancer surgery.
- The review covered enhanced recovery protocols, nutrition, exercise prehabilitation, smoking cessation, GLP-1 receptor agonists, and gut microbiome modulation.
- The abstract reports that enhanced recovery protocols reduce acute complications and shorten length of stay, and that smoking cessation improved wound healing and lowered pulmonary and infectious complications.
- Evidence for GLP-1 receptor agonists and microbiome-targeted interventions is described as emerging with limited clinical data, and the authors call for prospective studies.
Original abstract (PubMed)
OBJECTIVE: To evaluate current and emerging perioperative optimization strategies in genitourinary surgery and assess their potential to improve surgical outcomes, particularly in patients with modifiable risk factors. METHODS: A literature review was conducted using PubMed databases examining perioperative interventions relevant to patients undergoing surgery for genitourinary cancers. Areas of focus included enhanced recovery after surgery protocols, nutritional optimization, exercise prehabilitation, smoking cessation, glucagon-like peptide-1 receptor agonists, and gut microbiome modulation. Evidence from clinical trials, observational studies, systematic reviews, and current clinical guidelines was reviewed and synthesized. RESULTS: Current evidence supports the use of enhanced recovery after surgery protocols to reduce acute complications, shorten length of stay and decrease recovery time. Nutritional optimization and exercise prehabilitation demonstrated improved functional and metabolic capacity. Smoking cessation improved wound healing and decreased pulmonary and infectious complications. Emerging evidence suggests GLP-1 RAs offer metabolic benefits, and microbiome-targeted interventions may improve postoperative recovery through gut microbiome diversity preservation, although clinical data remains limited. CONCLUSIONS: Perioperative strategies demonstrate promising potential to improve outcomes in patients undergoing genitourinary surgeries by addressing modifiable risk factors. Further prospective studies are needed to guide clinical implementation.
-
Do glucagon-like peptide-1 receptor agonists influence cervical fusion outcomes? A systematic review and meta-analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of six propensity score-matched retrospective cohort studies, including 17,310 adults undergoing cervical fusion.
- Compared perioperative GLP-1 receptor agonist use against non-use in patients undergoing cervical fusion.
- No significant association was found for pseudarthrosis (OR 0.98, 95% CI 0.33-2.89), dysphagia (OR 0.89, 95% CI 0.38-2.05), readmission (OR 0.67, 95% CI 0.39-1.17), or device failure (OR 0.83, 95% CI 0.44-1.56).
- The authors conclude GLP-1RA use was not consistently linked to worse outcomes after cervical fusion and call for prospective, procedure-specific studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes, but their procedure-specific effects in cervical fusion remain unclear. METHODS: A systematic review and meta-analysis following PRISMA 2020 and MOOSE, prospectively registered in PROSPERO, searched PubMed, Embase, and Web of Science through April 28, 2026. Comparative studies evaluating perioperative GLP-1RA use in adults undergoing cervical fusion were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Random-effects meta-analyses were performed in Review Manager Web (RevMan Web). Certainty of evidence was assessed using the GRADE approach for clinically important outcomes. RESULTS: Six propensity score-matched retrospective cohort studies involving 17,310 patients were included. In the primary analyses, GLP-1RA use was not associated with significant differences in pseudarthrosis (odds ratio [OR] 0.98, 95% confidence interval [CI] 0.33-2.89; p = .96), dysphagia (OR 0.89, 95% CI 0.38-2.05; p = .68), hospital readmission (OR 0.67, 95% CI 0.39-1.17; p = .12), or device failure (OR 0.83, 95% CI 0.44-1.56; p = .41). Secondary outcomes were also not significantly different between groups. CONCLUSIONS: Perioperative GLP-1RA use was not associated with a consistent pattern of worse postoperative outcomes after cervical fusion. Prospective, procedure-specific studies with standardized exposure and outcome definitions are needed.
-
Perioperative management of GLP-1 receptor agonists: a structured narrative review with considerations relevant to neurosurgical patients.
AI summary of the abstract, unverified
- Structured narrative review of perioperative studies, gastric ultrasound reports, meta-analyses, and society guidance on GLP-1 receptor agonist use in anesthesia and surgery.
- The review focuses on neurosurgical factors such as urgent surgery, prone positioning, posterior fossa pathology, and baseline bulbar dysfunction.
- Evidence links GLP-1 receptor agonists with more gastric retention, especially during dose escalation, while population studies and meta-analyses show no rise in aspiration.
- The authors propose a risk-level-based perioperative approach but present it as expert extrapolation, not evidence-based neurosurgery guidelines, given limited neurosurgery-specific data.
Original abstract (PubMed)
PURPOSE: The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing in the treatment of obesity and type 2 diabetes mellitus. Some patients taking these medications undergo cranial or spinal surgical procedures. Delayed gastric emptying is a key mechanism of action for these medications. Despite the standard preoperative fasting period, there is a risk of residual gastric contents remaining in the perioperative period. Since neurosurgical patients face a risk of postoperative complications such as aspiration, delayed extubation, and postoperative nausea and vomiting, there is a need for a clinically focused review. METHODS: We performed a structured narrative review of perioperative studies, gastric ultrasound reports, meta-analyses, and professional society guidance addressing GLP-1RA use in anesthesia, surgery, and procedural sedation. Evidence was qualitatively synthesized with particular attention to procedural and physiologic factors relevant to neurosurgical practice, including urgent surgery, prone positioning, posterior fossa pathology, and baseline bulbar dysfunction. RESULTS: Current evidence consistently links the use of GLP-1 receptor agonists (GLP-1RAs) with an increased likelihood of gastric retention, particularly during dose escalation and in patients with active gastrointestinal symptoms. However, population-level studies and meta-analyses have not shown an increase in pulmonary aspiration rates. Although aspiration is not very common in neurosurgical patients, when it does occur, its consequences may be more severe than expected. Direct evidence specific to neurosurgery in the perioperative setting remains limited. CONCLUSION: A practical perioperative management approach structured according to risk level can assist in assessing the patient's symptoms and stage of treatment. It can also ensure that procedure-specific risk factors are taken into account, appropriate risk-reduction measures are selected, and the resumption of medication in the postoperative period is individualized. Due to the limited evidence specific to neurosurgery, these assessments should not be interpreted as evidence-based neurosurgery guidelines. They should instead be viewed as expert-driven extrapolations adapted from the broader perioperative literature to neurosurgical practice.
-
Impact of glucagon-like peptide-1 receptor agonists on outcomes following anterior cervical discectomy and fusion: a systematic review and meta-analysis.
AI summary of the abstract, unverified
- Systematic review and meta-analysis of eight retrospective cohort studies, covering 311,402 ACDF patients including 8,182 GLP-1RA users matched to non-users.
- Compared perioperative GLP-1RA use with non-use for pseudarthrosis, reoperation, dysphagia, deep vein thrombosis, and readmission after ACDF.
- Lower pseudarthrosis odds at 6 months (OR 0.60, 95% CI 0.52 to 0.71), 12 months (OR 0.62, 0.53 to 0.73), and 24 months (OR 0.67, 0.57 to 0.79).
- Findings for reoperation, dysphagia, deep vein thrombosis, and readmission were heterogeneous and inconsistent, so evidence on other complications is inconclusive.
Original abstract (PubMed)
OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes mellitus and obesity. Their metabolic, anti-inflammatory, and osteogenic effects raise important questions regarding their influence on spinal fusion. To date, no systematic review has specifically investigated how GLP-1RAs influence outcomes following the common anterior cervical discectomy and fusion (ACDF). This study aimed to evaluate the association between perioperative GLP-1RA use and outcomes following ACDF. METHODS: Following PRISMA guidelines, MEDLINE, Embase, PubMed, and the Cochrane Library were searched from inception to February 2026 for studies evaluating GLP-1RA exposure in the context of ACDF. Eligible studies included human observational cohort studies. Data were extracted independently by two reviewers. RESULTS: Eight retrospective cohort studies analysing 311,402 ACDF patients were included, of whom 8,182 were GLP-1RA users matched to non-users. Random-effects meta-analysis demonstrated significantly lower odds of pseudarthrosis among GLP-1RA users at 6 months (OR = 0.60, 95% CI: 0.52 to 0.71; I² = 16.6%), 12 months (OR = 0.62, 95% CI: 0.53 to 0.73; I² = 39.1%), and 24 months (OR = 0.67, 95% CI: 0.57 to 0.79; I² = 34.9%). Findings for reoperation, dysphagia, deep vein thrombosis, and readmission were heterogeneous and inconsistent across studies. CONCLUSION: Perioperative GLP-1RA use was associated with lower odds of pseudarthrosis. However, evidence regarding other postoperative complications remains inconclusive. Future prospective studies are required to further elucidate the impact of GLP-1RA use on ACDF outcomes. LEVEL OF EVIDENCE: Level III, therapeutic study.
-
Korean consensus-based recommendations for preanesthetic gastric ultrasound and anesthetic considerations for GLP-1 receptor agonist-based therapy: a consensus statement from Clinical Practice Guideline Committee of the Korean Society of Anesthesiologists.
AI summary of the abstract, unverified
- This is a Korean Society of Anesthesiologists consensus statement built from expert discussion and literature review, not a primary study with patient data.
- It covers when to use preanesthetic gastric ultrasound and how to interpret and act on findings, including GLP-1 receptor agonist therapy.
- For GLP-1 RA patients, it favors continuing the drug in most cases after individualized risk assessment, and it suggests considering a 24-hour clear liquid diet.
- The authors state the evidence is insufficient for evidence-graded guidelines and call for prospective outcome-based studies to refine these recommendations.
Original abstract (PubMed)
Pulmonary aspiration during anesthesia remains an uncommon but clinically significant perioperative complication associated with substantial morbidity and mortality. Although contemporary fasting guidelines recommend minimum fasting intervals to reduce aspiration risk, adherence does not guarantee an empty stomach, particularly in patients with delayed gastric emptying or those receiving medications that impair gastrointestinal motility, such as glucagon-like peptide-1 receptor agonist (GLP-1 RA)-based therapies. Preanesthetic gastric ultrasound has emerged as a practical point-of-care modality for the qualitative and quantitative assessment of gastric content and volume, enabling individualized aspiration risk stratification in selected patients. However, the current evidence base remains insufficient to formally support evidence-graded clinical practice guidelines. The consensus-based recommendations presented in this guideline were developed through expert discussion and review of the available literature, in which robust evidence is lacking. They provide practical guidance on the indications for preanesthetic gastric ultrasound, core examination principles and interpretation, integration of ultrasound findings into perioperative decision-making, management when gastric ultrasound is not feasible, and anesthetic strategies for patients with a full stomach. Special recommendations are included for patients receiving GLP-1 RA-based therapies, emphasizing the continuation of these medications in most patients with individualized risk assessment, consideration of a 24-h clear liquid diet, and the use of gastric ultrasound when delayed gastric emptying is suspected. Preanesthetic gastric ultrasound provides a practical bedside method for assessing gastric content and estimating aspiration risk in patients undergoing anesthesia. These recommendations are intended to support, not replace, clinical judgment and should be refined through future prospective outcome-based studies.
PubMed 42529794 Publisher (DOI) PubMed types: Consensus Statement, Journal Article, Review, Research Support, Non-U.S. Gov't -
Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.
AI summary of the abstract, unverified
- This ESGE and ESGENA guideline sets out graded recommendations on sedation for gastrointestinal endoscopy; it reports no sample size because it is not a primary study.
- Core recommendations cover informed consent that includes sedation, pre-assessment and enhanced monitoring for high-risk patients, and sedation matched to procedure complexity and delivered by trained staff.
- Agent-specific advice favors propofol first line depending on local resources and legislation, midazolam with opiates when analgesia is needed, and remimazolam for elderly or comorbid patients, with capnography for higher hypoxemia risk.
- Most recommendations rest on very low certainty evidence; only the environmental use of sedatives is rated moderate certainty, and structured education is rated low.
Original abstract (PubMed)
MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that informed consent for gastrointestinal endoscopic procedures should include consent for sedation and cover best practice as outlined in the ESGE Position Statement for informed consent.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend pre-assessment, a specific sedation regimen, and enhanced periprocedural monitoring in high-risk patients undergoing gastrointestinal procedures with sedation, to reduce the risk of sedation-related adverse events.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that pre-assessment, sedation regimen, and periprocedural monitoring should be determined by the complexity (duration, invasiveness) of the endoscopic procedure.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest that the management of sedation in patients on glucagon-like peptide-1 receptor agonists should be individualized. Conditional recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest offering the option of diagnostic colonoscopy and gastroscopy without sedation, based on the patient's and endoscopist's preference.Conditional recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that sedation should be provided by a dedicated healthcare professional trained in sedation administration and patient monitoring.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend propofol for procedural sedation, as first line, depending on the country's human resources, service framework, and legislation.ESGE and ESGENA recommend midazolam for procedural sedation, in combination with opiates when analgesia is required.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest the provision of the ultrashort-acting sedative remimazolam in elderly patients and patients with cardiovascular and/or respiratory comorbidities.Conditional recommendation, low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest exercising caution when combining ultrashort-acting sedatives with other sedatives or analgesics.Conditional recommendation, low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest capnography monitoring for patients undergoing sedated gastrointestinal endoscopy who are at higher risk of hypoxemia.Conditional recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that the use of reversal agents should be restricted to managing sedation-analgesia adverse events that do not improve with nonpharmacological intervention.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that patients be monitored after endoscopy by trained and qualified staff until the return of the patient's baseline observations.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest using scoring systems and standardized discharge checklists to facilitate patient readiness for discharge. Assessments should include a detailed record of vital signs, pain levels, and psychomotor performance.Conditional recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA suggest that the performing endoscopist holds the overall medicolegal responsibility for the patient's treatment, including safe recovery, but may delegate the assessment and discharge to trained and qualified personnel based on standardized discharge criteria.Conditional recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend that patients receive oral and written information regarding the post-endoscopy period. Contact details should be provided for potential delayed complications, emergencies, or readmission.ESGE and ESGENA recommend that patients undergoing sedated endoscopy have an accompanying person at discharge.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend performing emergency endoscopy under moderate sedation in hemodynamically stable patients. Alternatively, emergency endoscopy without sedation in cooperative patients is feasible.ESGE and ESGENA recommend sedation administration by an anesthesiology specialist in emergency endoscopy in patients at increased risk of aspiration, or with hemodynamic instability or significant comorbidities.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend consultation with anesthetic and obstetric teams involved in the pregnant patient`s care, together with the patient's choice for the appropriateness and choice of sedation during gastrointestinal endoscopy.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend improving and expanding educational offerings on sedation strategies and the principles of airway management, using structured training.Strong recommendation, low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend the development and implementation of a quality improvement program with performance indicators to monitor the quality of sedation practices in gastrointestinal endoscopy.Strong recommendation, very low certainty of evidence. MAIN RECOMMENDATIONS: ESGE and ESGENA recommend a rational use of sedatives to reduce the environmental impact of endoscopy.Strong recommendation, moderate certainty of evidence.
-
Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.
AI summary of the abstract, unverified
- This bibliometric study analyzed the 50 most-cited Web of Science publications on GLP-1 receptor agonists in plastic, aesthetic, and reconstructive surgery.
- Nearly all of these articles appeared between 2023 and 2025, the literature was led by the USA, and authorship and institutions were widely spread with no clear hubs.
- Three themes emerged: aesthetic aging with facial soft-tissue change, perioperative management and safety, and body contouring after drug-induced weight loss.
- The authors describe the field as rapidly expanding but conceptually immature and largely descriptive, and they call for prospective, outcome-driven studies.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists are increasingly prescribed for medical weight management and have rapidly gained relevance within plastic, aesthetic, and reconstructive surgery. Their widespread use has raised questions regarding perioperative safety, tissue quality, body contouring outcomes, and aesthetic aging, prompting a growing but fragmented body of literature. METHODS: A bibliometric analysis was conducted using the Web of Science Core Collection to identify the 50 most cited publications addressing the intersection of glucagon-like peptide-1 receptor agonists and plastic, aesthetic, or reconstructive surgery. Bibliographic data were extracted and analyzed to evaluate publication trends, citation performance, contributing authors and institutions, journals, geographic distribution, and thematic structures. Keyword co-occurrence and network analyses were performed to identify dominant research domains and emerging topics. RESULTS: Nearly all highly cited articles were published between 2023 and 2025, reflecting the recent and abrupt emergence of this field. The literature was geographically dominated by the USA and was distributed across a wide range of institutions and authors, without clear investigative hubs. Thematic analysis revealed three principal domains: aesthetic aging and facial soft-tissue changes, perioperative management and safety considerations, and body contouring following pharmacologically induced weight loss. Keyword clustering demonstrated an evolving shift from metabolic and bariatric contexts toward aesthetic and procedural decision-making. CONCLUSIONS: The literature on glucagon-like peptide-1 receptor agonists in plastic surgery is rapidly expanding but remains conceptually immature and largely descriptive. This bibliometric analysis highlights current research priorities, influential contributions, and critical gaps, underscoring the need for prospective, outcome-driven studies to inform evidence-based surgical practice. LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
-
Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.
AI summary of the abstract, unverified
- This single-center retrospective cohort of 750 adults undergoing breast cancer surgery (January 2024 to August 2025) compared patients with and without GLP-1 RA use.
- Exposure was active GLP-1 RA use within 30 days before surgery, verified by pharmacy records, in 209 patients versus 541 unexposed.
- Adjusted analyses found no link to SSI (AOR 1.28, 95% CI 0.81-2.03), seroma (AOR 1.22, 95% CI 0.83-1.79), or grade II+ flap necrosis (AOR 1.41, 95% CI 0.83-2.40).
- The authors concluded that perioperative GLP-1 RA use was not independently associated with short-term complications, and that multicenter studies are needed to confirm safety.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for diabetes and obesity, but their perioperative safety in breast cancer surgery remains uncertain. This study evaluated the association between perioperative GLP-1 RA use and 30-day postoperative outcomes after breast cancer surgery. MATERIALS AND METHODS: This retrospective cohort study included adults undergoing breast cancer surgery at a tertiary center (January 2024-August 2025). Exposure was active GLP-1 RA use within 30 days preoperatively, verified via pharmacy records. The primary outcome was a composite 30-day surgical morbidity endpoint (surgical site infection [SSI], flap necrosis ≥ grade II, seroma requiring aspiration, or implant/expander loss). Secondary outcomes included venous thromboembolism (VTE), readmission, reoperation, and length of stay. Multivariable regression and inverse probability of treatment weighting (IPTW) addressed confounding. RESULTS: The analytic cohort comprised 750 patients (209 exposed, 541 unexposed; median age 51 years). Exposed patients had higher body mass index and diabetes prevalence. After adjustment, GLP-1 RA exposure was not associated with SSI (adjusted odds ratio [AOR] 1.28, 95% CI 0.81-2.03), seroma (AOR 1.22, 95% CI 0.83-1.79), or flap necrosis ≥ grade II (AOR 1.41, 95% CI 0.83-2.40). No secondary outcome showed independent association with exposure. Prolonged length of stay (≥ 3 days) occurred in 26.8% of patients overall and was attributable primarily to drain management requirements, extent of surgery, and metabolic comorbidity rather than GLP-1 RA exposure. CONCLUSION: Perioperative GLP-1 RA use was not independently associated with increased short-term complications after breast cancer surgery. Multicenter studies are needed to confirm safety across settings.
-
Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.
AI summary of the abstract, unverified
- Single-center retrospective observational study of 15,902 elective EGD patients (August 2023 to May 2025), grouped by GLP-1RA exposure.
- Compared continued GLP-1RA use and a two-week hold against no use, with retained gastric contents as the primary outcome.
- Continued use carried higher RGC odds than no use (OR 10.68, 95% CI 3.74–30.55, p<0.001), while a two-week hold was not significantly different (OR 2.99, 95% CI 0.37–23.89, p=0.302).
- The authors conclude a two-week hold lowered RGC to a level comparable with no use, though obesity stayed higher-risk even after holding.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) slow gastric emptying and may therefore increase the risk of retained gastric contents (RGC). The optimal duration of discontinuation before esophagogastroduodenoscopy (EGD) under sedation or general anesthesia remains controversial. METHODS: We conducted a single-center, retrospective, observational study of patients who underwent elective EGD between August 2023 and May 2025. According to GLP-1RA exposure, patients were classified as (i) no GLP-1RA use, (ii) GLP-1RA continued use, or (iii) GLP-1RA two-week hold. The primary outcome was the presence of RGC, defined as any solid residue or > 100 mL of fluid visualized during EGD. Multivariate logistic regression was used to explore the relationship between GLP-1RA use and RGC. RESULTS: RGC occurred in 0.4% (63/15902) of patients with no GLP-1RA use, 5.83% (6/103) of patients with GLP-1RA continued use, and 1.61% (1/62) of patients with GLP-1RA two-week hold. GLP-1RA continued use was associated with a tenfold higher RGC risk versus no GLP-1RA use (odds ratio [OR] 10.68, 95% CI 3.74-30.55; p < 0.001), whereas a two-week hold reduced risk to a level statistically comparable with no GLP-1RA use (OR 2.99, 95% CI 0.37-23.89, p = 0.302). Obesity (BMI ≥ 28 kg/m2) independently increased RGC risk and, even after a two-week hold, yielded a tenfold higher risk of RGC versus no GLP-1RA use. Additionally, concurrent colonoscopy exerted a strong protective effect of RGC, and no RGC events occurred in patients with GLP-1RA two-week hold and concurrent colonoscopy. CONCLUSIONS: A two-week hold of GLP-1RA lowered RGC incidence to a low level comparable with no GLP-1RA use, especially in normal-weight or overweight patients and in those undergoing concurrent colonoscopy, but may be insufficient for obesity.
-
Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
AI summary of the abstract, unverified
- This is a narrative review, not a primary study, covering GLP-1 receptor agonist history, mechanism, and approved agents.
- It compares weight-loss effects across available GLP-1 receptor agonists and discusses their use alongside bariatric surgery.
- The review addresses perioperative considerations for surgical patients taking these drugs and proposes suggested recommendations.
- The abstract reports no quantitative data, so the recommendations' basis and specifics must be checked in the full text.
Original abstract (PubMed)
This article begins by providing historical insight into the discovery, development, and use of glucagon-like peptide-1 receptor (GLP-1R) agonist medications in the treatment of type 2 diabetes and obesity. Next, the mechanism of action and impacts of GLP-1R agonists are discussed, along with an overview of the Food and Drug Administration-approved GLP-1R agonists currently on the market. Comparison in effects on weight loss of the available GLP-1R agonists is briefly discussed, along with its use in the context of bariatric surgery. Finally, perioperative considerations for surgical patients using GLP-1R agonists are reviewed along with suggested recommendations.
-
GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.
AI summary of the abstract, unverified
- Narrative review synthesizing pharmacological, scintigraphic, observational, and consensus evidence on GLP-1 receptor agonists, gastric emptying, and endoscopy.
- Focuses on GLP-1RA exposure in patients undergoing endoscopy and its effect on gastric motility and retained gastric contents.
- Retained gastric contents and procedural disruptions are more frequent with GLP-1RAs in upper GI endoscopy, while reported aspiration rates are about 0.01%-0.05% for colonoscopy and under 0.3% for upper GI procedures.
- The authors favor continuing GLP-1RAs with dietary modification, risk assessment, selective gastric POCUS, and team communication rather than routine cessation, and note emerging prospective data on pre-procedural clear liquid diets.
Original abstract (PubMed)
The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction-associated steatotic liver disease (MASLD) has led to a higher use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) among patients undergoing gastrointestinal endoscopy. Although GLP-1RAs provide significant metabolic, cardiovascular, and hepatic benefits, their tendency to slow gastric emptying has raised concerns about retained gastric contents (RGC), procedural complications, and a greater risk of pulmonary aspiration during sedation or anesthesia. This review offers a translational narrative synthesis of mechanistic, physiological, and clinical evidence connecting GLP-1RA therapy to changes in gastric motility and peri-endoscopic outcomes. Data from pharmacological studies, scintigraphic evaluations, large observational cohorts, and international consensus statements are combined to guide physiology-based procedural decisions. Evidence consistently indicates that GLP-1RA exposure is associated with a higher incidence of RGC and more frequent procedural disruptions during upper gastrointestinal endoscopy. However, it remains uncertain whether RGC leads to clinically significant aspiration. Consistent with this, real-world data reveal no increase in aspiration pneumonia among GLP-1RA users undergoing colonoscopy, with reported aspiration rates of approximately 0.01%-0.05%. Likewise, during upper gastrointestinal endoscopy, only a small absolute rise in aspiration-related events has been observed, involving fewer than 0.3% of procedures. Current guidelines favor continuing GLP-1RA therapy alongside dietary modification, structured risk assessment, selective gastric point-of-care ultrasound (POCUS), and multidisciplinary communication, rather than routine cessation. Emerging prospective evidence indicates that implementing a pre-procedural clear liquid diet, with individualized timing of weekly agents, may reduce the risk of clinically significant RGC, complementing existing dietary preparation strategies.
-
Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
AI summary of the abstract, unverified
- This narrative translational review explores whether GLP-1 receptor agonists could serve as a pharmacological adjunct to multimodal prehabilitation before major abdominal surgery.
- It covers the biological rationale, sarcopenic obesity, implications for oncologic surgery and neoadjuvant therapy, and emerging data from bariatric and metabolic surgery.
- It highlights perioperative safety concerns, particularly delayed gastric emptying and aspiration risk, along with current anesthetic guidance.
- The authors state there is currently no direct evidence for this use and propose prospective studies to test feasibility, safety, and clinically meaningful outcomes.
Original abstract (PubMed)
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), including semaglutide and tirzepatide, are increasingly prescribed for obesity and type 2 diabetes and have demonstrated substantial and rapid weight loss in large randomized trials. At the same time, prehabilitation before major abdominal surgery has become an established perioperative strategy to improve postoperative outcomes. This review explores the potential role of GLP-1RAs as a pharmacological adjunct in multimodal surgical prehabilitation. We discuss the biological rationale for metabolic optimization, the relevance of sarcopenic obesity, potential implications for oncological surgery and neoadjuvant therapy, and emerging data from bariatric and metabolic surgery. We also highlight important perioperative safety considerations, particularly delayed gastric emptying and aspiration risk, and current anesthetic guidance. Although integration of GLP-1RAs into prehabilitation pathways is biologically plausible and clinically attractive, there is currently no direct evidence supporting their use in this setting. We propose that GLP-1RAs represent a promising and testable strategy for metabolic optimization in surgical patients. Prospective studies are required to evaluate feasibility, safety, and impact on clinically meaningful outcomes. This framework is hypothesis-generating and aims to inform future translational research at the interface of metabolic medicine and perioperative care.
-
Temporal trends in patient demographics and postoperative outcomes in metabolic and bariatric surgery: a longitudinal analysis of the MBSAQIP database in the GLP-1 era.
AI summary of the abstract, unverified
- Database analysis of MBSAQIP centers in the United States comparing sleeve gastrectomy, bypass, and revision cases from 2015 and 2023.
- Calendar year is the exposure, framed as the GLP-1 receptor agonist era, though the abstract does not report GLP-1RA use directly.
- Primary BMI fell modestly (sleeve 45.3 to 44.9, bypass 46.6 to 45.9, both P<.001) while ASA scores were unchanged; revisional BMI, ASA, and comorbidities rose.
- The authors conclude that perioperative outcomes improved across all procedures, which they present as evidence of safety in the current GLP-1 era.
Original abstract (PubMed)
BACKGROUND: Utilization of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss has substantially increased in recent years, yet it remains unclear how the characteristics of patients pursuing metabolic and bariatric surgery (MBS) have evolved during this time. OBJECTIVES: This study compares patient characteristics and perioperative outcomes for primary and revisional MBS procedures from 2015 to 2023. SETTING: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) participating centers in the United States. METHODS: The MBSAQIP database was queried to identify all sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and revision/conversion procedures (revision). Preoperative body mass index (BMI), American Society of Anesthesiologists (ASA) score, number of comorbidities, and perioperative outcomes were analyzed longitudinally. RESULTS: The number of procedures increased from 2015 to 2023 (SG: 91,553 vs 129,475; RYGB: 43,143 vs 60,312; revision: 23,138 vs 26,478). For primary MBS, average BMI decreased (SG: 45.3 [8.3] vs 44.9 [7.8], P < .001; RYGB: 46.6 [8.6] vs 45.9 [8.0], P < .001), while ASA scores did not change. Number of comorbidities decreased for SG (1.6 [1.4] vs 1.5 [1.4], P < .001) but remained the same for RYGB. For revisional procedures, average BMI (39.4 [9.7] vs 41.1 [8.5]; P < .001), ASA score (2.7 [.5] vs 2.8 [.5], P < .001), and number of comorbidities (2.3 [1.4] vs 2.6 [1.4], P < .001) increased. Perioperative outcomes improved for all procedures. CONCLUSIONS: Primary MBS is now being performed in patients with lower average BMI, while revisional cases are performed in patients with higher BMI and more comorbid conditions. Despite this, perioperative outcomes have improved, highlighting the safety of modern MBS in the modern GLP-1 era.
-
Impact of Obesity, Sarcopenia, and Nutritional Status on Spine Surgery Patients.
AI summary of the abstract, unverified
- This narrative review covers obesity phenotypes, sarcopenic obesity, and nutritional deficiency in spine surgery patients, with no pooled sample or effect sizes reported.
- The authors argue that body mass index alone misses fat distribution, muscle quality, and nutritional status, all of which affect perioperative risk.
- Central adiposity and sarcopenic obesity are described as independent predictors of wound complications, mechanical failure, and delayed recovery, and nutritional deficiencies may impair fusion.
- The review proposes a preoperative optimization framework using dietary counseling, resistance prehabilitation, and multidisciplinary care, and calls GLP-1 receptor agonists a promising option.
Original abstract (PubMed)
Obesity, sarcopenia, and malnutrition are increasingly recognized as key determinants of outcomes in spine surgery. Reliance on body mass index alone does not capture variations in fat distribution, muscle quality, or nutritional status, each of which affects perioperative risk. Central adiposity and sarcopenic obesity are independent predictors of wound complications, mechanical failure, and delayed recovery. Nutritional deficiencies in obese and postbariatric patients, including low levels of vitamin D, iron, and protein, can further impair bone healing and fusion. Emerging evidence supports structured preoperative optimization through dietary counseling, resistance-based prehabilitation, and coordinated multidisciplinary management. Glucagon-like peptide-1 receptor agonists represent a promising pharmacologic option that improves metabolic control and facilitates weight reduction without the malabsorption associated with bariatric surgery. This review summarizes current understanding of obesity phenotypes, sarcopenic obesity, and nutritional deficiency in spine patients and presents a practical framework for preoperative optimization to reduce complications, enhance fusion rates, and improve long-term surgical outcomes.
-
Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
AI summary of the abstract, unverified
- This is a review article covering how GLP-1 receptor agonists affect otolaryngology and head and neck surgery.
- Delayed gastric emptying raises perioperative aspiration concern, so anesthetic guidance on cessation and fasting matters for safety and scheduling.
- The review describes benefit for obstructive sleep apnea in patients with obesity, with possible relevance to sinusitis, olfaction, hearing loss, and facial appearance.
- Animal studies suggested thyroid cancer risk, but population studies are inconclusive and the authors call for long-term investigation of causality.
Original abstract (PubMed)
The number of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing. Beyond diabetes and weight management, these medications have various effects within the head and neck with both beneficial and potentially adverse clinical implications. Delayed gastric emptying may contribute to reflux, chronic cough, and potential aspiration in the perioperative setting; as such, physicians should be aware of anesthetic guidelines (duration of pre-operative cessation, pre-operative fasting or liquid diet) to improve safety and avoid operative delay. GLP-1RAs have shown benefit in treating obstructive sleep apnea in those with obesity or overweight and may become increasingly relevant in multimodal treatment of sleep disorders. GLP-1 receptor signaling is involved in sinopulmonary inflammatory cascades and recent evidence suggests clinical implications for chronic sinusitis and olfactory disorders. Previously reported neuroprotective effects have led to investigation regarding potential benefit in neurotoxicity-associated hearing loss. Muscle atrophy with weight loss may contribute to a gaunt, aged appearance leading patients to seek facial rejuvenation, or to a patulous eustachian tube and changes in conductive hearing. Animal studies suggested an increased risk of thyroid cancer, but population studies have been inconclusive and will require long-term investigation to determine any causal relationship.
-
History of GLP-1 receptor agonists confer no improvement for Achilles tendon repairs: A national, propensity-matched comparison.
AI summary of the abstract, unverified
- Retrospective cohort using de-identified electronic health records from a multi-institutional network, comparing GLP-1RA users with non-users in the year before Achilles tendon repair (2015–2024).
- One-to-one propensity matching on age, sex, race, and five comorbidities produced two cohorts of 853 patients each.
- No significant differences in 1-year re-rupture (OR 1.41, 95% CI 0.70–2.81) or surgical site infection (OR 0.71, 95% CI 0.43–1.19); absolute 1-year rates among users were 1.5% and 1.7%.
- The authors conclude GLP-1RA use was not associated with improved tendon healing or lower re-rupture, and other secondary outcomes were similarly distributed.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to influence musculoskeletal repair pathways, but their clinical impact on tendon healing following Achilles tendon repair (ATR) remains unclear. PURPOSE: Although emerging evidence suggests GLP-1RAs may modulate inflammation, preserve muscle, and promote tenogenic differentiation, no large-scale study has evaluated their effect on post-ATR outcomes. STUDY DESIGN: This retrospective, cohort study analyzed a multi-institutional research network of de-identified electronic health records, identifying patients who underwent ATR between 2015 and 2024 and stratifying them based on GLP-1RA use within one year prior to surgery. METHODS: Primary outcomes included Achilles re-rupture, strain or re-injury, wound dehiscence, and surgical site infection at 90 days and 1 year postoperatively, with secondary outcomes including deep vein thrombosis, pulmonary embolism, tibial or sural neuropathy, and opioid use. One-to-one propensity score matching was performed for age, sex, race, and five comorbidities. RESULTS: Among the two matched cohorts of 853 patients each, no statistically significant differences were observed in 1-year re-rupture (OR 1.41 [0.70-2.81]) or surgical site infection (OR 0.71 [0.43-1.19]) (p > 0.01 for all comparisons), with all other outcomes similarly distributed. Absolute complication rates among GLP-1RA users aligned with established benchmarks, including a 1-year re-rupture rate of 1.5% and surgical site infection rate of 1.7%, with all outcome differences versus non-users remaining within a 5% margin. CONCLUSION: Despite their theorized regenerative benefits, GLP-1RAs were not associated with improved tendon healing or lower re-rupture rates following ATR, suggesting their use does not necessitate changes to perioperative management or risk stratification practices.
-
What obgyns need to know about GLP-1 receptor agonists.
AI summary of the abstract, unverified
- This narrative review synthesizes current evidence on GLP-1 and dual GLP-1/GIP receptor agonists for obstetric and gynecologic practice, with a focus on women's health.
- Phase 3 trials report 15-21% body weight reduction, with tirzepatide described as superior to semaglutide, and PCOS meta-analyses report improved insulin resistance, androgen levels, and ovulation rates.
- Manufacturer guidance advises backup contraception for 4 weeks after tirzepatide initiation or dose escalation, because the drug significantly delays gastric emptying.
- Early human cohort studies of inadvertent early pregnancy exposure report no increased risk of major congenital malformations, which the authors describe as preliminary reassurance.
Original abstract (PubMed)
PURPOSE OF REVIEW: Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists. This review synthesizes evidence on these agents, focusing on their relevance in women's health. RECENT FINDINGS: GLP-1 receptor agonists and dual agonists achieve 15-21% body weight reduction in phase 3 trials, with tirzepatide demonstrating superior efficacy compared to semaglutide. Key populations of interest include patients with polycystic ovary syndrome (PCOS), pregnant patients, and those undergoing gynecologic surgery. In women with PCOS, meta-analyses confirm improvements in insulin resistance, androgen levels, and ovulation rates. Tirzepatide significantly delays gastric emptying, prompting manufacturer guidance to use backup contraception for 4 weeks after initiation or dose escalation. Emerging human cohort studies of inadvertent early pregnancy exposure report no increased risk of major congenital malformations, providing preliminary reassurance despite animal teratogenicity data. Perioperative guidance has evolved from blanket discontinuation to individualized, risk-stratified approaches. SUMMARY: GLP-1 receptor agonists offer benefits across the lifespan, with promising applications in PCOS and preconception optimization. Reproductive-aged women need counseling regarding contraception and preconception discontinuation. Knowledge gaps include the need for pregnancy registries. Obstetrician-gynecologists will increasingly encounter these therapies and must navigate evolving evidence regarding their safety, efficacy, and clinical implications.
-
Glucagon-like Peptide-1 as a Promising Marker of Postoperative Intestinal Ischemia After Abdominal Aortic Surgery.
AI summary of the abstract, unverified
- Prospective single-center cohort of 80 patients undergoing elective abdominal aortic surgery, with serum GLP-1 measured at eight perioperative time points.
- Intestinal ischemia was confirmed by contrast-enhanced MRI or surgery, and six patients developed it; GLP-1 was compared between those with and without ischemia.
- Patients with ischemia had significantly higher GLP-1 at all postoperative time points (P < 0.02), with AUC 0.993 at 24 hours and 0.919 at 6 hours after declamping.
- The authors conclude that elevated GLP-1 shows high specificity for ischemia, independent of diabetes or age, and is a promising predictive biomarker.
Original abstract (PubMed)
BACKGROUND: Acute intestinal ischemia is a severe postoperative complication of abdominal aortic surgery, and delayed diagnosis markedly limits therapeutic options. At present, no reliable biochemical marker for early detection is available. This study assesses whether perioperative changes in glucagon-like peptide-1 (GLP-1) may serve as an early biomarker of postoperative intestinal ischemia. METHODS: This prospective single-center cohort study enrolled 80 patients undergoing elective abdominal aortic surgery. Total serum GLP-1 concentrations were measured at 8 perioperative time points spanning the preoperative, intraoperative, and postoperative periods. Intestinal ischemia was diagnosed using contrast-enhanced magnetic resonance imaging or surgical confirmation. RESULTS: The perioperative time course of GLP-1 was similar across all patients, with peak concentrations consistently observed 24 hr after complete declamping during vascular reconstruction. Six patients developed intestinal ischemia; these individuals exhibited significantly higher GLP-1 levels at all postoperative time points than patients without ischemia (P < 0.02). GLP-1 demonstrated the highest predictive ability at 24 hr after complete declamping (area under the receiver operating characteristic curve [AUC] 0.993); similarly, measurements obtained at 6 hr after complete declamping exhibited excellent predictive performance (AUC 0.919). CONCLUSION: Perioperative elevation of GLP-1 demonstrates high specificity for intestinal ischemia, independent of diabetes mellitus or age. Serum GLP-1 concentrations show promise as reliable predictive biomarkers for postoperative intestinal ischemia, with the best diagnostic accuracy observed at 6 and 24 hr after complete declamping during vascular reconstruction.
-
Perioperative Nutritional Optimization in Total Joint Arthroplasty: From Screening to Supplementation.
AI summary of the abstract, unverified
- This targeted narrative review searched PubMed/MEDLINE and Google Scholar for nutritional optimization strategies in total hip and total knee arthroplasty patients.
- It covers biochemical screening, vitamin D, vitamin C, magnesium, micronized purified flavonoid fraction, essential amino acids, and carbohydrate loading.
- Vitamin D deficiency affects 13 to 63% of TJA patients and is consistently associated with more complications, poorer function, and higher infection risk.
- The authors conclude that perioperative nutritional optimization is safe and evidence-supported, and that integrating it into prehabilitation may reduce complications.
Original abstract (PubMed)
BACKGROUND: Malnutrition and suboptimal nutrient status are increasingly recognized as modifiable risk factors influencing outcomes after total joint arthroplasty (TJA). Older adults and medically complex patients are particularly vulnerable to perioperative catabolism, impaired wound healing, and delayed functional recovery. This review synthesized current evidence on perioperative nutritional optimization, including biochemical screening, micronutrient correction, essential amino acid (EAA) supplementation, and adjunctive metabolic strategies, to support recovery in patients undergoing total hip arthroplasty and total knee arthroplasty. METHODS: A targeted narrative literature review was performed using PubMed/MEDLINE and Google Scholar databases. Search terms included combinations of "total joint arthroplasty," "total knee arthroplasty," "total hip arthroplasty," "malnutrition," "albumin," "vitamin D," "vitamin C," "essential amino acids," "HMB," "arginine," "glutamine," "bioflavonoids," "micronized purified flavonoid fraction," "carbohydrate loading," and "GLP-1 receptor agonists." Priority was given to randomized controlled trials, systematic reviews, meta-analyses, and large observational studies with direct relevance to arthroplasty populations. RESULTS: Vitamin D deficiency (13 to 63% of TJA patients) is consistently associated with increased complications, impaired functional scores, and higher infection risk, with favorable outcomes observed after targeted repletion. Vitamin C improves collagen synthesis, decreases inflammatory markers, reduces pain, and lowers the incidence of complex regional pain syndrome. Magnesium supports vitamin D activation, analgesia, and collagen stability. Bioflavonoids, particularly micronized purified flavonoid fraction, demonstrate high-quality evidence for reducing postoperative swelling and improving early motion after total knee arthroplasty. The use of EAA supplementation preserves quadriceps muscle mass, improves strength recovery, and accelerates return to activities of daily living. Carbohydrate loading mitigates postoperative insulin resistance, and glucagon-like peptide-1 receptor agonists offer metabolic benefits but require individualized perioperative management. CONCLUSIONS: Perioperative nutritional optimization, including vitamin D repletion, vitamin C, magnesium support, micronized purified flavonoid fraction therapy, and structured EAA supplementation, represents a safe, accessible, and evidence-supported strategy to enhance recovery after TJA. Integrating targeted nutrition into prehabilitation pathways may help reduce complications and support faster functional gains.
-
Perioperative and Renal Outcomes After Nephrectomy in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists: A Pilot Study.
AI summary of the abstract, unverified
- This retrospective national claims study matched 980 patients on GLP-1RAs 1:1 to 980 controls, all with BMI ≥27 kg/m² undergoing nephrectomy for renal neoplasms.
- The exposure was GLP-1RA therapy within 180 days of surgery, compared with matched patients not receiving it, with outcomes assessed at 30 and 90 days.
- GLP-1RA use was associated with lower 90-day AKI (OR 0.76; P = .031), lower MAKE (OR 0.56; P = .004), and lower 30-day readmission (OR 0.72; P = .011).
- The authors conclude that GLP-1RAs may mitigate postoperative risk without increasing gastrointestinal, respiratory, or systemic morbidity.
Original abstract (PubMed)
INTRODUCTION: Patients with elevated BMI undergoing nephrectomy are at increased risk of acute kidney injury (AKI) and perioperative complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer renal-protective and anti-inflammatory effects while reducing perinephric adiposity. Thus, we aimed to determine whether GLP-1RA use is associated with fewer perioperative complications following nephrectomy. METHODS: We conducted a retrospective, national claims analysis of patients undergoing nephrectomy from June 2021 to October 2025. Patients with BMI ≥ 27 kg/m2 undergoing nephrectomy for renal neoplasms were included. Patients receiving GLP-1RA therapy within 180 days of surgery were 1:1 propensity matched by demographics (age, sex, race), comorbidities (body mass index, chronic kidney disease, hypertension, hyperlipidemia, diabetes mellitus, tobacco use), and metformin/sodium-glucose cotransporter-2 inhibitor use. Outcomes included 30-day and 90-day adverse events overall and stratified by partial and radical nephrectomy. RESULTS: After 1:1 matching, 980 individuals on GLP-1RAs were well balanced with 980 controls from a pool of 36,382 eligible patients. At 30 days, GLP-1RA use was associated with lower rate of hospital readmission (odds ratio [OR] = 0.72; P = .011). At 90 days, GLP-1RA users had a reduced incidence of venous thromboembolism (OR = 0.62; P = .035) and readmission (OR = 0.62; P < .001). Those on GLP-1RA therapy had significantly lower odds of 90-day AKI (OR = 0.76; P = .031) and major adverse kidney events (MAKEs; OR = 0.56; P = .004). MAKE was significantly lower for partial (OR = 0.45; P = .0024) and radical (OR = 0.54; P = .0014) nephrectomy. CONCLUSIONS: Preoperative GLP-1RA use appeared to reduce rates of AKI, MAKE, and 30/90-day readmission among patients undergoing nephrectomy. These findings suggest GLP-1RAs may mitigate postoperative risk without increasing gastrointestinal, respiratory, or systemic morbidity.
-
Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis.
AI summary of the abstract, unverified
- Database study of metformin-treated T2DM patients undergoing primary TKA, split by obesity status and propensity matched 1:1.
- The exposure was GLP-1RA use within three months of surgery, compared with patients not using GLP-1RAs.
- Obesity subgroup: GLP-1RA use was linked to less anemia (OR 0.714; P = 0.001), 90-day readmission (OR 0.776; P = 0.001), and two-year aseptic loosening (OR 0.498; P = 0.037).
- Nonobese patients had lower 90-day readmission (OR 0.514; P = 0.004) and ED visits (OR 0.649; P = 0.024); authors report reduced resource use irrespective of obesity.
Original abstract (PubMed)
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been linked to improved outcomes following total knee arthroplasty (TKA). However, it remains unclear whether the observed benefits are attributable to weight loss, glycemic control, or first-line type 2 diabetes mellitus (T2DM) medications such as metformin. This study aimed to evaluate the impact of perioperative GLP-1RA use on TKA outcomes in T2DM patients stratified by obesity status. METHODS: The TriNetX Global Collaborative Network was queried using relevant Current Procedural Terminology and ICD-10 codes for metformin-treated T2DM patients aged 18 years or older undergoing primary TKA. Patients were divided into two groups based on obesity status and further stratified based on GLP-1RA use within three months of surgery. The groups were propensity matched (1:1) based on age, sex, body mass index (BMI), HbA1c, and comorbidities. Surgical outcomes, medical complications, and resource utilization were assessed at 90 days and 1 year. Surgical outcomes and revision rates were also assessed at two years. RESULTS: In obese patients (n = 8,170), GLP-1RA use was associated with notable reductions in postoperative anemia (odds ratio [OR] 0.714; P = 0.001), acute kidney injury (OR 0.755; P = 0.021), 90-day readmission (OR 0.776; P = 0.001), emergency department (ED) visits (OR 0.836; P = 0.008), and aseptic loosening at two years (OR 0.498; P = 0.037). These patients also demonstrated greater postoperative reductions in BMI and HbA1c. In nonobese patients (n = 1,328), GLP-1RA use was similarly associated with lower rates of 90-day readmission (OR 0.514; P = 0.004) and ED visits (OR 0.649; P = 0.024), although no notable differences in other outcomes were observed. CONCLUSION: Among metformin-treated T2DM patients undergoing TKA, GLP-1RA use was associated with reduced resource utilization irrespective of obesity. However, additional reductions in medical complications and aseptic loosening were observed in the obese group, suggesting a potential synergistic effect between weight loss and glycemic control. These findings highlight the effectiveness of GLP-1RAs in optimizing high-risk candidates undergoing TKA.
-
Association of GLP-1 inhibitors with cardiovascular outcomes in patients undergoing coronary artery bypass surgery.
AI summary of the abstract, unverified
- Retrospective review of a prospectively maintained cardiac surgery database covering nonemergent isolated CABG patients from 2010 to 2024, with 4170 having complete medication data.
- Preoperative GLP-1 users (165 patients, 3.9%) were compared with nonusers using multivariable Cox models for all-cause mortality, MACCE, and 30-day mortality.
- After adjustment, no significant difference in all-cause mortality or MACCE was found between the groups.
- GLP-1 use was associated with less new-onset postoperative atrial fibrillation (14% vs 22%; P = .02), which the authors say warrants further study.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated cardiovascular benefit in patients with diabetes and obesity. Patients undergoing coronary artery bypass grafting (CABG) often have similar cardiovascular risk profiles. Therefore, this study sought to investigate the impact of preoperative GLP-1 use in patients undergoing CABG. METHODS: A retrospective review of a prospectively maintained cardiac surgery database was conducted. Patients undergoing a nonemergent isolated CABG between 2010 and 2024 were stratified by GLP-1 users and nonusers. Multivariable Cox proportional hazards regression models were used to assess the risk of all-cause mortality, major adverse cardiovascular and cerebral events (MACCE), and short-term 30-day mortality. Variables for multivariable adjustment were selected by variable importance of random forest models. RESULTS: A total of 11,389 patients underwent isolated CABG, of whom 4170 had complete medication data. Among these, 165 patients (3.9%) were on GLP-1 for a median of 353 days. GLP-1 users were younger and more likely to be female, diabetic, hypertensive, and to have a higher body mass index. GLP-1 users had a longer intensive care unit length of stay, although the overall length of stay was similar in the 2 groups. In adjusted analysis, no significant difference in all-cause mortality or MACCE was found between groups. Notably, GLP-1 use was associated with a significantly lower incidence of new-onset postoperative atrial fibrillation (14% vs 22%; P = .02). CONCLUSIONS: Preoperative GLP-1 use in CABG patients was not associated with an increased risk of mortality or MACCE. GLP-1 use was associated with reduced postoperative atrial fibrillation, which warrants further investigation of GLP-1's potential perioperative benefits in larger studies.
-
Impact of GLP-1 Agonist on Surgical Wound Complications after Plastic and Reconstructive Surgery: A Propensity-Matched Cohort Large Database Analysis.
AI summary of the abstract, unverified
- A retrospective propensity-matched cohort from the TriNetX database examined 30-day wound complications after panniculectomy, abdominoplasty, or breast reduction.
- Patients on GLP-1 receptor agonists were compared with non-users, with diabetes, vascular disease, cancer, and smoking excluded.
- Matched complication rates were 4.7% vs 2.7% for panniculectomy (P = 0.05), 9.8% vs 3.6% for abdominoplasty (P = 0.001), and 2.6% vs 1.3% for breast reduction (P = 0.035).
- The authors conclude GLP-1 RA use was associated with more surgical site complications across all procedures and support preoperative counseling and perioperative planning.
Original abstract (PubMed)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained Food and Drug Administration approval for management of type 2 diabetes. However, they have been increasingly used for their weight loss side effect profile. Surgical site wound complications have been observed in patients using these medications (although with a low incidence rate). Given the paucity of literature on weight loss medications and their implications in plastic surgery, this study evaluates the impact of weight loss medication use on postoperative surgical site outcomes in patients undergoing common plastic and reconstructive procedures. METHODS: The TriNetX National Health Research database was queried to identify patients undergoing panniculectomy, abdominoplasty, or breast reduction. Patients with diabetes; peripheral vascular diseases; nutritional, metabolic, or endocrine diseases; a history of cancer; or smoking were excluded. Propensity matching analysis was performed to balance the cohorts. Postoperative outcomes, specifically surgical wound infections, breakdown, or dehiscence within 30 days after the procedure, were assessed based on GLP-1 RA use status. RESULTS: The risk of surgical site wound healing complications in patients taking GLP-1 RAs compared with those not on these medications was statistically significantly higher before cohort matching as well as after matching. Matched cohort results were as follows: 4.7% versus 2.7% for panniculectomy ( P = 0.05), 9.8% versus 3.6% for abdominoplasty ( P = 0.001), and 2.6% versus 1.3% for breast reduction ( P = 0.035), respectively. CONCLUSIONS: Use of GLP-1 RAs was associated with higher rates of surgical site complications across all evaluated procedures. This underscores the necessity of patient counseling regarding the implications of these weight loss medications before surgery, along with the potential need for a strategic perioperative management plan to enhance surgical outcomes.
-
Nutritional Challenges in Post-Massive Weight Loss Body Contouring: Guidance for Plastic Surgeons on GLP-1 Agonists and Sleeve Gastrectomy.
AI summary of the abstract, unverified
- This narrative review addresses nutrition for patients with massive weight loss undergoing body contouring, focusing on sleeve gastrectomy and GLP-1 receptor agonist use.
- Sleeve gastrectomy carries fewer malabsorptive risks than gastric bypass but still predisposes patients to iron, vitamin B12, and protein deficiencies.
- GLP-1 receptor agonists such as semaglutide and tirzepatide suppress appetite and delay gastric emptying, which may further reduce protein and micronutrient intake.
- The authors recommend individualized protein timing, micronutrient correction, and supplementation, noting that many patients fall short of the 60 to 120 g/day protein guideline.
Original abstract (PubMed)
With obesity affecting more than 40% of US adults, bariatric surgery has become a cornerstone of obesity treatment, resulting in massive weight loss but also significant nutritional challenges. As demand for body contouring surgery after bariatric surgery increases, plastic surgeons must understand how evolving weight loss strategies, particularly the widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) and the shift to laparoscopic sleeve gastrectomy, affect nutritional status and wound healing. Laparoscopic sleeve gastrectomy presents fewer malabsorptive risks than Roux-en-Y gastric bypass, but still predisposes patients to deficiencies in iron, vitamin B12, and protein due to reduced intake and food intolerance. The rise of GLP-1 medications, such as semaglutide and tirzepatide, presents new considerations. These agents suppress appetite and delay gastric emptying, which can further reduce protein and micronutrient intake. For patients on GLP-1 RAs undergoing body contouring surgery, nutritional strategies must be tailored to ensure adequate perioperative protein and caloric intake, emphasizing timing, such as spacing protein throughout the day and increasing intake through small, more frequent meals. Protein deficiency, which impairs collagen production, angiogenesis, and immunity, is a key risk factor for poor wound healing. Despite guidelines recommending 60 to 120 g/day of protein, many patients fall short, particularly those losing weight on GLP-1 RAs. Perioperative nutritional optimization, including individualized protein timing plans, aggressive correction of micronutrient deficiencies, and supplementation strategies, is essential. This review provides comprehensive recommendations for plastic surgeons caring for patients with massive weight loss, including those using GLP-1 RAs, to optimize surgical outcomes and minimize complications.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
-
GLP-1 Receptor Agonists versus Bariatric Surgery: A Global Health Network Analysis of Panniculectomy Outcomes.
AI summary of the abstract, unverified
- Retrospective TriNetX database study of 24,645 panniculectomy patients from 150 organizations (2020–2025), comparing prior GLP-1 RA users (n = 6,060) with prior bariatric surgery patients (n = 4,142).
- Propensity matching on age, sex, race, HbA1c, BMI, and triglycerides was used to compare postoperative complications between the two exposure groups.
- GLP-1 RA users had lower odds of cellulitis (OR 0.62, 95% CI 0.47 to 0.83; P = 0.0015), seroma (OR 0.77, 95% CI 0.59 to 0.89; P = 0.026), and hemorrhage (OR 0.51, 95% CI 0.30 to 0.89; P = 0.016).
- The authors conclude that patients who lose weight with GLP-1 RAs may have fewer complications after panniculectomy than those who had bariatric surgery, and they note the GLP-1 RA group had higher BMI, HbA1c, and LDL.
Original abstract (PubMed)
BACKGROUND: With the increase in medically assisted weight loss, procedures such as panniculectomy are becoming more common. The surgical impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remains unclear, particularly compared with bariatric surgery. The authors compared panniculectomy outcomes and perioperative laboratory values in patients with previous GLP-1 RA use versus bariatric surgery. METHODS: The TriNetX Global Research Network was queried to identify patients who underwent panniculectomy after either GLP-1 RA use or bariatric surgery. Cohorts were formed using codes (eg, Current Procedural Terminology, International Classification of Diseases, 10th Revision) and perioperative laboratory values were compared between groups, including hemoglobin A1c (HgA1c), body mass index (BMI), low-density lipoprotein, triglycerides, and albumin. Propensity score matching for age, sex, race, HbA1c, BMI, and triglyceride levels was performed to stabilize baseline metabolic profiles and allow balanced comparison of postoperative outcomes, including cellulitis, hematoma, seroma, hemorrhage, wound dehiscence, surgical site infection, and abscess formation. RESULTS: Data from 177,467,699 patients across 150 health care organizations (2020 through 2025) were analyzed. Among all patients who underwent panniculectomy ( n = 24,645), 6060 had preoperative GLP-1 RA use and 4142 had previous bariatric surgery. GLP-1 RA users exhibited higher perioperative triglycerides, HbA1c, BMI, and low-density lipoprotein (all P < 0.05). Multivariable regression demonstrated lower odds of cellulitis (odds ratio [OR], 0.62 [95% CI, 0.47 to 0.83]; P = 0.0015), seroma (OR, 0.77 [95% CI, 0.59 to 0.89]; P = 0.026), and hemorrhage (OR, 0.51 [95% CI, 0.30 to 0.89]; P = 0.016) in the GLP-1 RA cohort. CONCLUSION: Patients who achieve weight loss with GLP-1 RAs, as opposed to bariatric surgery, may experience fewer postoperative complications after panniculectomy.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.